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INFLUENCE OF OVERWEIGHT ON ROUTINE PARAMETERS OF RENAL FUNCTION IN 
DOGS 
 
Obesity is one of the most common nutritional disorders in dogs and its prevalence has 
grown exponentially in recent years alongside with obesity in humans. It is from an 
accumulation of adipose tissue in such a way that it affects the patient health. In humans, a 
chronic increase of body weight is a risk factor to develop renal dysfunction. Therefore, the 
purpose of this study was to investigate the effect of weight gain on renal function in dogs. 
Renal function was determined using traditional markers of renal dysfunction (blood urea 
nitrogen and creatinine, urine specific gravity and urine protein-creatinine ratio). A total of 16 
beagles were studied, 8 non-obese, which kept a stable ideal body weight, and the remaining 
8, gradually increased weight for 24 weeks. Both groups were fed a commercial adult 
maintenance diet high in fat and protein. The obese group was fed 1.3 times more than the 
maintenance energy requirements, resulting in an average of 0.328 kg increase in weight per 
month. Renal markers were measured at times 1, 12 and 24 weeks and the results did not 
showed a significant difference between the groups. These results suggest that the degree of 
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RESUMO:   
 
 A INFLUÊNCIA DO EXCESSO DE PESO EM PARÂMETROS DE AVALIAÇÃO DA 
FUNÇÃO RENAL DE ROTINA  
 
A obesidade, uma das doenças nutricionais mais comuns em cães tendo a sua prevalência 
crescido exponencialmente nos últimos anos, a par com a obesidade nos humanos. É uma 
doença crónica que advém do excesso de acumulação de tecido adiposo de tal forma que 
afeta a saúde. No homem, uma condição corporal aumentada é um fator de risco para 
disfunção renal. O objetivo deste estudo foi investigar o efeito do aumento de peso sobre a 
função renal em cães. A função renal foi determinada através de marcadores renais 
convencionais de insuficiência renal (ureia e creatinina sérica, densidade urinária, rácio 
proteína-creatinina de urina). Um total de 16 beagles foram usados, 8 não obesos que 
mantiveram um peso corporal estável, e os 8 restantes, que aumentaram progressivamente 
o peso durante 24 semanas. Ambos os grupos foram alimentados com uma dieta comercial 
de manutenção, rica em gordura e proteína. Ao grupo obeso foi fornecido 1,3 vezes mais 
que os requisitos energéticos de manutenção, fazendo com que este grupo aumenta-se 
0,328kg mais por mês. Os marcadores renais foram medidos às 1, 12 e 24 semanas em 
ambos os grupos, não tendo demonstrado diferenças significativas, sugerindo que o grau de 
excesso de peso obtido neste estudo não causa alterações na função renal. 
 
 
Palavras-chave: obesidade, excesso de peso, canideo, insuficiência renal, obesidade 
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PART I - INTERNSHIP REPORT 
 
As part of the Integrated Master’s Degree in Veterinary Medicine from the Faculty of 
Veterinary Medicine, University of Lisbon, I completed the internship with a total duration of 
six months. The internship took place in the Laboratory of Animal Nutrition, Department of 
Nutrition Genetics and Ethology, at the Faculty of Veterinary Medicine of the Ghent 
University, from the end of January to the end of June 2016. In this Laboratory work 
researchers from all over the world, who perform studies in the areas of nutrition, conduct 
food-related experiments with dogs, cats, chickens, ponies, pigeons and pigs for third 
parties, but also do nutritional analysis in the framework of services and clinic. Furthermore, 
the staff provides dietary advice to veterinarians, pet owners, businesses, government and 
other agencies. These include clinical consultations concerning dietetics. The main 
research themes of the lab are feed intake regulation and energy homeostasis, the impact 
of nutrition on intestinal microbiota and host physiology, the role of nutrition in immune 
competence and inflammatory diseases and the role of trace elements in the metabolism.  
I had the opportunity to experience a new working environment and interact with highly 
dedicated scientists on a daily basis. The atmosphere was friendly and people were 
welcoming, which contributed to a memorable experience. 
During these months, I performed tasks in the area of clinical nutrition of small animals, 
under the supervision of Prof. Dr. Myriam Hesta. My supervisor also gave me permission to 
follow her nutritional advice consultations as well as nutrition classes with other master 
students at the hospital. I also had the pleasure to work with Daisy Liu, who gave me the 
opportunity to follow and help in her PhD research about the effect of obesity on renal 
function in dogs. Based on this study I was able to develop and write my Master’s 
dissertation about the “Influence of overweight and obesity on some parameters (creatinine, 
blood urea nitrogen (BUN), urine protein\creatinine ratio (UPCR) and specific gravity) of the 
renal function in dogs”. 
With the support from resident students Veerle Vandendriessche and Wendy Wambacq 
and the teaching assistant Sophie Dupont, and based on our weekly meetings and the 
nutrition clinical cases they gave me to resolve, I was able to gain a broad range of skills in 
a short period of time. I performed literature review and analyzed different clinical nutrition 
cases in dogs and cats in the literature to include in my project. I gained valuable 
knowledge on interpreting the nutritional necessities in different life stages and also in 
different disease stages, and how nutrition can treat specific disease conditions such as 
allergies or food intolerances, nephrology bladder stones. I also learnt, at an advanced 
level, to understand and be more critical about commercial feed, and I improved my English 
language skills considerably. 
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In summary, this internship, with its challenges and opportunities, contributed for the 




PART II - REVIEW ON OBESITY/OVERWEIGHT AND KIDNEY DYSFUNCTION 
 
I. Introduction  
In recent years, obesity has become an escalating global problem in humans. It has 
become a significant worldwide health epidemic, especially in developing countries, and is 
already considered the disease of the twenty-first century (WHO, 2016). The World Health 
Organization (WHO) estimates that 39% of adults (aged 18 years and over) were 
overweight in 2014, and 13% were obese (WHO, 2016). In 1980 the numbers were quite 
different, with 23.2% of the population being overweight and only 5.4% were effectively 
obese (WHO, 2016). This means that the prevalence of obesity more than doubled 
between 1980 and 2014 (WHO, 2016). The same is happening with our pets: the 
prevalence of pet obesity is increasing (German, 2006a; Raffan, 2013; Sandøe, Palmer, 
Corr, Astrup & Bjørnvad, 2014). 
This health problem is not just the accumulation of large amounts of adipose tissue, but is 
also associated with important metabolic and hormonal changes in the body (Zoran, 2010). 
Obesity also leads to a reduction in longevity in dogs. A study carried out with a group of 48 
Labrador retrievers showed that the group with dietary restriction remained leaner and lived 
longer (median lifespan of 13 years compared to 11.2 years for the moderately overweight 
group) (Kealy, et al., 2002; Lawler et al., 2005; Osto & Lutz 2015). Obesity in humans is 
widely recognized as a risk factor for cardiovascular disease and for various metabolic 
disorders such as type II diabetes and hypertension, but also kidney diseases (German, 
2006a). Actually, increases in chronic kidney disease (CKD) prevalence have paralleled 
increases in the prevalence of overweight and obesity in humans (Hall et al., 2014). 
However, studies have indicated that even in the absence of diabetes type II or systemic 
arterial hipertension, which together account for more than 75% of all cases of end-stage 
renal disease (ESRD), obesity itself can contribute to kidney damage or has a negative 
impact on the progression of renal disease (Griffin, Kramer &  Bidani, 2008; Hall et al., 
2014).  
Similar relationships may hold true for dogs. However, there isn’t an evident correlation 
between obesity and kidney disease yet in this species. Experimentally induced obesity in 
dogs performed by Henegar et al. (2001) showed that blood pressure, pulse rate, 
glomerular filtration rate (GFR) and renal plasma flow were all significantly higher in obese 
versus non-obese dogs. Also, at histological analyses the kidney structure of obese dogs 
demonstrated enlarged Bowman’s space, increased glomerular cell proliferation, increased 
mesangial expansion and thickened basement membranes, and increased expression of 
renal transforming growth factor (TGF). However, the glomerulosclerosis scores for obese 
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versus lean dog kidneys were not statistically different (Henegar et al., 2001). In another 
study that was performed with obese pet dogs in a weight-loss program showed that the 
increased levels of biomarkers of renal injury (homocysteine, cystatin, and clusterin) and 
the increased urine protein to creatinine ratios improve after weight-loss (Tvarijonaviciute et 
al., 2013). Based on this assumption, the present master dissertation consists primarily of a 
critical evaluation of the pathogenic potential of obesity, which may be responsible for the 
development of progressive renal disease in obese dogs, irrespective of other common 
obesity-related diseases. Knowledge of obesity/overweight as a risk factor for renal disease 
can heighten awareness and target health screening of dogs. And with more evidence from 
canine research studies as a tool, practitioners may be able to advocate more strongly for 
obesity prevention and weight reduction plans for their clients' pets.  
The present dissertation is divided into 3 parts: the first is a brief description of the 
completed internship; the second part includes a review of the literature on the problem of 
overweight and obesity in dogs and the effect of overweight on renal function with focus on 
the possible pathophysiological mechanisms, and in the final of this part there is also a 
briefly discussion about the nutritional concerns when a dog has obesity and renal 
insufficiency; the last part aims to demonstrate the study and the results of the study in 
question, as well as the discussion of then.  
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II. The Problem of Obesity 
Due to the emphasis on dogs as respected and valued members of society, the goals of 
canine nutrition, defined as longer life, higher quality of life and better performance, are now 
similar to that of human nutrition (Toll, Yamka, Schoenherr & Hand, 2010). Besides this 
positive factor, nowadays, it is also more and more common to see pet owners consider 
their pets as family members (Toll et al., 2010). This human-animal bond is characterized 
by an excessive anthropomorphic or anthropocentric behavior. Food and other factors play 
an important role in this relationship, and are responsible for the most common nutritional 
disorder in companion animals in industrialized countries, obesity (Kienzle, Bergler & 
Mandernach, 1998). This chapter will approach the problem of obesity in dogs, showing its 
dimension in our society, as well as the factors that can predispose dogs to this problem 
and the consequences that it can bring. 
1 DEFINING THE PROBLEM 
1.1 Definition of overweight and obesity 
Obesity has been defined as excessive fat accumulation that may result in a significant 
impairment of health, and is the most common nutritional disorder in companion animals 
(National Institutes of Health. 1985; German, 2006a; Zoran, 2010; Laflamme, 2006). This 
state of energy imbalance is due to excessive dietary intake or inadequate energy utilization 
(German, 2006a). Accumulation of fat is achieved by increasing the number of fat cells 
(hyperplastic obesity) and/or due to increasing the size of fat cells (hypertrophic obesity) 
(Burkholder & Toll 2010). Body composition studies of dogs indicate that animals judged to 
be in ideal body condition have 15 to 25% body fat (Laflamme, 1997; European Pet Food 
Industry Federation, 2013). When body fat exceeds 30-40%, the animal is considered 
obese, while the excess of 25-35%, the animal is considered overweight (Burkholder et al, 
2010; European Pet Food Industry Federation, 2013). 
1.2 Prevalence of overweight and obesity  
Recent years have seen a drastic increase in the rates of overweight and obesity among 
humans living in developed countries (German, 2006a; Zoran, 2010; Sandøe et al, 2014). 
The worldwide prevalence of obesity in adults aged 18 years and over more than doubled 
between 1980 and 2014 (WHO, 2016). The reported prevalence in dogs in several studies 
in United States of America (USA), Europe and Australia was between 22 percent and 44 
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percent, although there are differences in prevalence in the literature that may reflect 
differences in sampling (e.g., who has been asked (owners or vets) or local variations) 
(Sandøe et al., 2014; McGreevy et al., 2005; Robert & Reither, 2004). In dogs, some 
investigators agree that the prevalence of pet obesity is increasing in a similar fashion to 
human obesity (German, 2006a). In 2016, in USA, the Association for Pet Obesity 
Prevention (APOP) has estimated that 53.9% of USA dogs are overweight or obese, which 
was 1.4% more than in 2012 (Association for Pet Obesity Prevention, 2016). This means, in 
2015, 41.9 million US dogs were estimated to be overweight or obese, from a total 77.8 
million US dogs, according to American Pet Products Association (APPA) source data from 
2016 (Association for Pet Obesity Prevention, 2016). In the United Kingdom (UK), another 
new report from People's Dispensary for Sick Animals  (PDSA) Animal Welfare estimates 
that around 40% of dogs in the UK are thought to be overweight or to obese, and that the 
proportion of overweight pets will continue to rise (PDSA Animal Welfare, 2017).  
In general, specialists agree that the nutrition-related disorder most seen in companion 
animals nowadays is the excess weight gain (Sandøe et al., 2014). This statistic is clinically 
relevant since obesity is not only a huge accumulation of adipose tissue but also involves 
important changes at the metabolic and hormonal level in the body (Sandøe et al., 2014). 
Therefore, there is clinical relevance for deciding whether the animal has an ideal, 
overweight or obese body condition since these two last scenarios might negatively affect 
an animal’s health. Although, there is no ideal method to evaluate the body condition, many 
different methods exist. 
2 DIAGNOSTIC   
In the common routine most of the veterinarians diagnose obesity only through visual 
inspection. The subjectivity inherent in this practice makes this a method less sensitive from 
a clinical perspective. The assessment of body composition using objective measurements 
can identify and quantify excess of body weight (BW) and can set an optimal weight. 
Methods that estimate of the correct percentage of body fat (% BF) are the most accurate 
procedure to diagnose obesity (Toll et al., 2010; Laflamme, 2006; Case, Carey, Hirakawa & 
Daristotle, 2000). 
Diagnosis of overweight and obesity in humans is relatively simple, requiring only 
measurement of height and weight to calculate body mass index (BMI) (BMI >25 is 
overweight) (WHO, 2016). In dogs, due to body conformation variations across breeds, the 
variation of frame size within breeds and age variation, the diagnosis of overweight and 
obesity is more difficult (German, 2006b). There is no ideal, definitive method for deciding 
whether a dog is in a thin, ideal, overweight or obese body condition (Toll et al., 2010; 
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German, 2006b). Many different systems have been developed for the measurement fat 
mass (FM) and lean body mass (BM) in companion animals, but few have been validated 
for use as routine tests due to some lack of accuracy, price or practicability (Toll et al., 
2010; German, 2006b). These systems can also be classified into two categories: the 
clinically relevant techniques and the research techniques (Table 1). The next sections will 
discuss some of these techniques in detail. The most widely adopted procedures in the 
clinical routine are the quantitative procedures, namely the BW measurement combined 
with body condition score (BCS), which is preferred above other morphometric methods 
(Toll et al., 2006; German, 2006b; Elliott, 2006a).  
 
Table 1 - Methods for body composition analysis in dogs (adapted from German, 2006b) 
Clinical techniques Advantage Disadvantage 
BW 
 
Objective, easy and quick to 
use  
Has little meaning when it’s used 
alone 
BCS Easy and quick to use and 
doesn´t required any 
equipment 
Subjective and needs experience 
Tape measurements Easy, quick and cheap There are not many studies that 
relate the pelvic circumference to 
the % body fat 
BMI  Easy, quick and cheap Needs to be breed specific  
Skinfold thickness 
measurement 





simple, safe, quick, 
noninvasive 
Many variables to control 
(hydration status, consumption of 
food and water, skin and air 
temperature, recent physical 
activity, conductance of the 
examination table, patient age, 
size, shape and posture in addition 
to electrode positioning)  
Research techniques Advantage Disadvantage 
 Dilution techniques  
- Total body water 
- Extracellular fluid  




Expensive equipment and labor for 
analyses, the assumption of the 
hydration (can change with age, 
sex, species, breed or disease) 





radiation exposure, accurate 
for limb lean and fat 
specialized radiology technician 
required and also anesthesia. 
BW (body weight); BCS (body condition score); BMI (body mass index); DEXA (Dual energy x-ray 
absorptiometry  
2.1 Common clinical methods  
The combination of BW and BCS has been used to define criterion for canine obesity, 
because these parameters are easier to measure than body fat (Freeman, et al., 2011). 
2.1.1  Body weight and Relative Body Weight  
A complete physical exam should include an assessment of BW. BW is the simplest 
technique and it provides an approximate measure of the total energy stored in the body 
(Elliott, 2006a). Although BW by itself distinguish say if the patient is overweight, 
underweight, or in ideal body condition, when it's used complementarily with another 
method it´s very useful, e.g., BCS (German, 2006b; Burkholder, 2000a; Case et al., 2000). 
Furthermore, BW can vary from day to day, so it is important to use the same method for an 
individual animal each time to avoid more external variation (German, 2006b; Burkholder, 
2000a; Case et al., 2000).  
Relative body weight (RBW) in terms of an animal’s ideal weight has been selected as a 
criterion for diagnosing obesity since it is easier to measure BW than body fat (Burkholder, 
2000a; Case et al., 2000). RBW is the ratio between the current weight an animal and its 
estimated optimal weight (Burkholder, 2000a; Case et al., 2000). An overweight dog’s RBW 
range is on average between 10 and 20% above the optimal weight and for obese dogs it is 
20% or more above the ideal weight (Toll et al., 2010; Burkholder, 2000a). Although easy to 
apply, this method presents some critical issues. Establishing an optimum weight is a 
challenging task for the veterinarian. Domestic canids are the most diverse mammalian 
species in terms of weight and body size. Burkholder (2000a) suggest that BW is recorded 
when the animal reaches adulthood as a reference. Most dogs reach adult weight at 12 
months, and large breeds may reach it only at 18 months (e.g. Bernese Mountain, 
Bullmastiff, Dogue de Bordeaux) (Hand et al., 2010). Nonetheless, if an animal does not 
have access to nutrition that satisfies their nutritional needs during growth, mature adult 
weight may not match their optimal weight. In cases of pure breeds, the American Breeder 
Club establishes the averages of optimal weights, although even in the same breed the 
optimum weight may differ 25% or more (Toll et al., 2010). Thus, determining the optimal 
weight requires some care.  
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2.1.2 Morphometric measurements  
Morphometry is a technique that comprises of a set of simple, economic and non-invasive 
procedures to assess body composition using different body parameters (German, 2006b; 
Toll et al., 2010, Eliiot, 2010). According to German (2006b), there are 3 main methods, 
which are the BCS, the measurement of skinfold thickness and the dimensional 
evaluations. 
2.1.2.1  Skinfold thickness measurement 
This morphometric analysis is based on the relationship between the thickness of 
subcutaneous fat layer and total body fat (Elliott, 2006a). It is widely used in humans to 
calculate the %BF from measurements of the thickness of the subcutaneous fat layer that 
lies between the dermis and muscle (Elliott, 2006a). In dogs, this layer is deposited in 
significant quantities in the thoracic region, the lumbar, coccygeal areas and the intra-
abdominal region, usually with a higher fat deposition in the lumbar region (Toll et al., 
2010). Unfortunately, the skin in dogs is easily detached from the subcutaneous adipose 
tissue making skinfold measurement impractical and unreliable in this species (Elliott, 
2006a). 
2.1.2.2  Dimensional evaluations  
Dimensional evaluations estimate mathematically and statistically the %BF by the 
measurements of various anatomic circumferences and lengths (Fig.1) (Elliot, 2010). Waist 
circumference measurement in humans, a simple and practical procedure, is an 
approximate index of intra-abdominal fat and total %BF (WHO, 2000). Burkholder (2000a) 
refer to two studies that show that the measurement of pelvic circumference in dogs is 
proportional to the amount of fat and that this is the dimension that alters the most with 
increasing weight, like in humans (Burkholder, 2000a). In these studies they measured 
diferents parts of the animal’s body and convert this measurements into a equation (tablet 
2) to estimate the percent body fat. The choosen measures to creat these equation was the 
height at the shoulder (HS) measured in centimeters and the pelvic circumference (PC) at 
the level of the flank measured in centimeters too. The pelvic circumference measurements 
is the one who change most with weight gain in the dogs. The reasonable correlation 
existed between the %BF calculations (using gender-specific or gender nonspecific 
equation) was determined by DEXA (Burkholder, 2000a; Mawby et al., 2004). However, to 
obtain reliable results of %BF through the equations, the dog cannot exceed the weight 
limits of the studied groups (7.3 to 34.5 kg) and the %BF limits obtained (from 1% to 33%). 
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Because of the variaion in body types among breeds these measurements may not always 
correlate well with %BF (Burkholder, 2000a; Mawby et al., 2004). Despite this, the 
advantage of these evaluations is that they would be helpful to convince the owners that 
their animals are indeed overweight and in need of weight loss (Burkholder, 2000a; Mawby 
et al., 2004). 




Table 2 - Equations for converting morphometric measurements into fat mass percentages 
(Adapted from Mawby et al., 2004). 
Dogs 
Gender specific formula: 
% BF in males = -1.4 (HS in cm) + 0.77 (PC in cm) + 4 
% BF in females = -1.7 (HS in cm) + 0.93 (PC in cm) + 5 
 
Non-gender specific formula: 
% BF in both sexes = -0.0034 (HS in cm)2 + 0.0027 (PC in cm)2-1.9 / BW(kg) 
BF – body fat; Cm – centimeters; HS- hock stifle; PC- pelvic circumference at the level of the flank; BW – body 
weight; Kg – kilogram  
2.1.2.3 Body condition scores 
BCS is a semi-quantitative but subjective method for evaluating body composition, 
particularly the percentage of body fat, and for estimating the degree of over- and 
underweight (Freeman et al., 2013; European Pet Food Industry Federation, 2013; Michel, 
2012; Elliot, 2010; Toll et al., 2010; German, 2006b; Burkholder, 2000a).  
This scoring system requires prior training and observer experience to carefully follow the 
criteria that are defined, which are the visual assessment of the pet and palpation to assess 






European Pet Food Industry Federation, 2013; Elliot, 2010; Toll et al 2010). Various 
systems of 3-, 5-, 6- and 9-points were proposed (Elliott, 2006a; Hand et al., 2010). The two 
most common in clinical practice are 5- (Edney and Smith, 1986) and 9-point systems 
(Laflamme, 1997), where the classification for ideal body condition is 3 and 5, respectively. 
The most widely accepted and validated system is the 9-point system (European Pet Food 
Industry Federation, 2013; Hand et al, 2010; German et al. 2006; Burkholder, 2000a; 
Laflamme, 1997). Laflamme (1997) demonstrated a good correlation between BCS and 
%BF measured with DEXA, a noninvasive technique that can be used to estimate body 
composition, in which for each unit increase in BCS on a nine-point scale there is 
approximately 5% increase in body fat (Burkholder, 2000a). Moreover, studies show good 
concordance between BCS measurements from diferent experienced observers (Raffan et 
al., 2006; Mawby et al., 2004). 
Table 3 shows the BCS (9-point and 5-point system) in dogs, including a description of the 
palpation location and the corresponding percentages of body fat as well as the increase or 
decrease of BW under or above optimal BW. Using the BCS in conjunction with BW gives a 
clinician a more complete perspective on a patient’s body condition and provides a good 
basis for determining energy requirements (Michel, 2012; Burkholder, 2000a). The 
combination of these two measures can be extremely helpful for owners that usually do not 
recognize if their animal is overweight or obese and thus may contribute to the success of 
weight-loss programmes (Toll et al., 2010). 
 
Table 3 - Guide to 9-point and 5-point Body Condition Scores in dogs (European Pet Food 

















Ribs and bony prominences are visible and 
easily palpable with no fat cover. Severe 
abdominal tuck when viewed from the side and 
an exaggerated hourglass shape when viewed 
from above. Tail base prominent, raised bone 
structures with no tissue between the skin and 
bone. Obvious loss of muscle mass and no 
discernible body fat. 




Ribs and bony prominences are visible and 
easily palpable with no fat cover. Severe 








and a marked hourglass shape when viewed 
from above. Tail base prominent, raised bone 
structures with no tissue between the skin and 
bone. Minimal loss of muscle mass. 




Ribs and bony prominences are easily 
palpable with minimal fat cover. Marked 
abdominal tuck when viewed from the side and 
an obvious waist when viewed from above. Tail 
base raised bony structures with little tissue 
between skin and bone. 





Ribs and bony prominences are easily 
palpable with minimal fat cover. Abdominal 
tuck when viewed from the side, and a 
well-proportioned waist when viewed from 
above. Tail base raised bony structures with 
little subcutaneous tissue. 




Ribs and bony are not visible, but easily to 
palpable with thin layer of fat, as well other 
bony prominences are palpable with a slight fat 
cover. Abdominal tuck is present when viewed 
from the side, and a well-proportioned lumbar 
waist when viewed from above. 
Tail base smooth contour or some thickening, 








Ribs and bony prominences can be felt under 
a moderate fat cover. Abdominal tuck and 
waist are less pronounced. Tail base smooth 
contour or some thickening, bony structures 










Ribs and bony prominences can be felt under 
a moderate fat cover. Little abdominal tuck 
when viewed from side or waist, and back 
slightly broadened when viewed from above. 














Ribs and bony prominences are difficult to 
palpate, under a thick fat cover. Other bony 
prominences are distended with extensive fat 
deposit. Tail base appears thickened, difficult 
to palpate bony structures. General ventral 
bulge under abdomen, no waist, and back 
markedly broadened when viewed from above. 







Ribs and bony prominences are very difficult to 
feel under a thick fat cover between bone and 
skin.  
Tail base appears thickened, bony structures 
almost impossible to palpate.  
General pendulous ventral bulge under 
abdomen, no waist, back markedly broadened 
when viewed from above.  
Fat deposits over lumbar area, neck, face, 
limbs and in the groin. A dip may form on the 






2.2 Research techniques 
Body fat can be accurately measured by other sophisticated techniques, e.g. dilution 
techniques, bioelectrical impedance analysis, computerized axial tomography, magnetic 
resonance imaging, total organic determination of potassium and DEXA (German, 2006b). 
Often, these methods are expensive and require specialized equipment and/or general 
anesthesia and are not practical or available for clinical applications (German, 2006b; Elliot, 
2010). DEXA is a noninvasive and quick technique to measure the bone mineral, whole 
body fat, and non-bone lean mass (Son, d’Avignon & Laflamme, 1998). Because it is easily 
adaptable for use in small animals, it has been extensively studied and used to determine 
an accurate estimation of body composition in dogs (Toll, Gross, Berryhill & Jewell, 1994; 
Munday, Booles, Anderson, Poore & Earle, 1994; Mawby et al., 2004;). This x-ray 
technique uses photons of two different energy levels (70 and 140 kVp) (Mawby et al., 
2004). These two different energy levels cross differently through the bone, the muscle and 
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the fat, (Elliott, 2006b), which allows one to calculate the mineral density, the lean mass 
and the fat mass with a high degree of precision (Toll et al., 1994; Munday et al., 1994; 
Elliott, 2006b). However, this technique is neither practical nor economical for common use 
in veterinary clinics, because dogs must be sedated or anesthetized for the procedure and 
requires expensive initial set-up costs and experienced personnel to interpret results 
(Gosselin, Wren & Sunderland, 2007; Lauten, Cox, Brawner & Baker, 2001). 
3 ADIPOSE TISSUE  
Adipose tissue has been considered throughout the years as a diffuse and wrongly defined 
tissue with as main role the storage of energy in the form of triglyceride, and insulation and 
protection of other body organs. Nowadays, adipose tissue is considered to be a much 
more complex organ containing a variety of cell types (Zoran, 2010; German, Ryan, 
German, Wood & Trayhurn, 2010a). In this chapter, a brief overview of the characteristics 
of adipose tissue (histology, distribution and physiology) and new perspectives of this tissue 
will be given. 
3.1 Histology 
Adipose tissue is a special kind of conjunctive tissue which, although containing adipocytes 
as the most prevalent cells (about 50%), comprises of various others types of cells, 
including pre-adipocytes, mesenchymal stem cells, fibroblasts, endothelial cells, pericytes, 
and immune cells such as macrophages, dendritic cells, mast cells, granulocytes and 
lymphocytes, as well as nerve cells bound to the autonomic nervous system (Haugen & 
Drevon, 2007; Sethi & Vidal-Puing, 2007; Sharkey, 2007; Prins, 2002). The primary and 
popular classification of adipose tissue divides this tissue into two types: white adipose 
tissue (WAT) and brown adipose tissue (BAT) (Zoran, 2010; Joazeiro, 2008; Haugen et al., 
2007).  
WAT is characterized by cells that contain only a droplet of fat and whose colour, 
depending on the type of diet, can range between white or yellowish, which is due to 
accumulation of carotenes dissolved in fats (Joazeiro, 2008). These adipocytes can 
accommodate much larger lipid droplets than any other cell type (Haugen et al., 2007). 
These cells have a considerable capacity for expansion and when filled with lipids they 
become spherical (Joazeiro, 2008). In one mature white adipocyte the lipid droplet 
comprises approximately 85% of the cellular volume, and the nucleus and other organelles 
are usually compressed against the cell membrane (Haugen et al., 2007; Joazeiro, 2008). 
Therefore, they differ in size, having diameters of up to 100 µm, which is larger than most 
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other cell types (Haugen et al., 2007). Although considered unilocular lipid droplets, when 
viewed under the electron microscope these cells also have, in addition to the main lipid 
droplet, much smaller droplets, however devoid of surrounding membrane (Joazeiro, 2008). 
BAT is different from WAT because of the presence of multilocular lipid droplets, whose 
colour is due to the abundant vascularization and numerous mitochondria present in the 
cytoplasm (Joazeiro, 2008; Haugen et al., 2007). This tissue is actively involved in 
thermogenesis and is found in higher proportions in neonates (Haugen et al., 2007; 
Joazeiro, 2008). 
However, in obesity multiple changes occur in the adipose tissue. In obesity an excess of 
caloric intake causes the adipose depots to expand (Fuster, Ouchi, Gokce, Walsh, 2016). 
This expansion is mediated by an increase in adipocyte numbers (hyperplasia) and an 
enlargement of adipocyte size (hypertrophy) (Fuster et al., 2016). The hyperplasia is 
mediated by the formation of functional adipocytes (adipogenesis) (Fuster et al., 2016). In 
contrast, adipocyte hypertrophy typically leads to lipid-laden, dysfunctional adipocytes that 
undergo cell death and contribute to adipose tissue inflammation and dysfunction (Cildir, 
Akincilar, Tergaonkar, 2013). These quantitative and qualitative changes in the cellular 
composition of adipose tissue are mainly composed of mononuclear cells, such as 
macrophages, the most abundant immune cell in the adipose tissue of obese individuals 
(Cildir et al., 2013). Studies in animals demonstrate that adipose tissue expansion is 
accompanied by macrophage infiltration, and switch in macrophage activation to a more 
proinflammatory state, and also high expression of inflammatory cytokines (Weisberg et al., 
2003; Lumeng, Bodzin, Saltiel, 2007). Also, there is recruitment of T cells, B cells, 
macrophages, neutrophils, and mast cells that are increased in visceral adipose tissue of 
obese individuals or diet-induced obese mice (Cildir et al., 2013). By contrast, specific 
subsets of T cells – helper T cell type 2, regulatory T cell, and invariant natural killer T cell – 
and eosinophil numbers are decreased in the obese adipose tissue (Cildir et al., 2013). 
3.2 Adipogenesis 
Stem cells and pre-adipocytes play an indispensable role in the expansion of adipose tissue 
that occurs in obesity (Fischer-Posovaszky et al., 2007). These cells are recruited when 
existing adipocytes reach a critical level of hypertrophy, and consequently in adipose tissue 
hyperplasia (Trujillo & Scherer, 2006). The peroxisome proliferator-activated receptor y 
(PPARy) and the CCAAT / enhancer binding protein α (C / EBPα) are the main regulators 




WAT is mainly distributed between the subcutaneous and visceral compartments. The 
subcutaneous level forms the adipose panicle, a layer disposed between the dermis and 
the muscular layer. At the visceral level, the deposits are located at the thoracic 
(mediastinal) and abdominal (omental, mesenteric, perirenal, retroperitoneal, parametrial, 
periovaric and epididymal) levels (Sharkey, 2007; Trujillo et al.,2006). In humans, the 
pathologic consequence of obesity is mainly influenced by the deposition of fat into visceral 
deposits instead of subcutaneous deposits (Saisho et al., 2013; Kley, Caffall, Tittle, 
Ferguson, Hoenig 2008). This phenomenon has been called metabolic syndrome in 
humans, and is associated with abdominal obesity (accumulation of visceral adipose 
tissue), blood lipid disorders, inflammation, insulin resistance or type II diabetes, and 
increased risk of developing cardiovascular disease (Ader et al., 2014; Hoenig, Traas & 
Schaeffer, 2013). Similar symptoms have been reported in dogs too (Hoenig, Pach, 
Thomaseth, Devries & Ferguson, 2012; German et al.,2009 ). However, a true metabolic 
syndrome has not described, which may be due to differences in risk factors for 
cardiovascular disease and blood lipid abnormalities (Hoenig et al., 2012; German et 
al.,2009). 
BAT has a more limited and residual distribution in the adult, surrounding most of the vital 
organs (heart, kidney, aorta, circulatory routes, among others) (Sharkey, 2007; Trujillo et 
al.,2006). 
3.4 Physiological functions 
There are various functions of adipose tissue that make it a vital organ. In addition to the 
classical functions of adipose tissue, including thermal insulation (fats are poor heat 
conductors) and mechanical protection, adipose tissue is recognized mainly because of the 
large energy storage in the form of triglycerides (Zoran, 2010; Sharkey, 2007; Prins, 2002). 
During periods of increased ingestion and/or decreased energy expenditure, the surplus 
energy is effectively stored in WAT in the form of lipids, mainly triglycerides (TG). These are 
hydrolysed in free fatty acids (FFA) and glycerol by the action of lipoprotein lipase. These 
FFA penetrate into the adipocytes and are transported, intracellular, through the fatty acid 
binding proteins. They are activated on Acyl-CoA and esterified in the endoplasmic 
reticulum in different classes of lipids like TG, phospholipids and cholesterol esters. 
Subsequently, these energy reserves are used by the body in situations of caloric 
restriction, physical exercise and between meals, in order to meet the energy needs of 
other organs (Haugen et al., 2007; Beylot, 2007). 
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The mobilization of TGs is made from lipolysis (hydrolysis of intracellular TG), which results 
in the release of glycerol and fatty acids. Glycerol is used at the gluconeogenesis level to 
synthesize new glucose molecules. Fatty acids are circulated in the form of non-esterified 
fatty acids (NEFAs), transported by albumin, which will later be used by muscles 
(oxidation), liver [complete CO2 oxidation, incomplete ketone bodies, synthesis of TG, 
secretion and storage of very low density lipoproteins, (VLDL)] and adipose tissue (re-
esterification of fatty acids), for example (Haugen et al 2007; Beylot, 2007). In normal 
conditions the adipocyte has the capacity to integrate a significant number of hormonal and 
nervous signals, in order to maintain an adequate balance between synthesis (lipogenesis) 
and catabolism (lipolysis) of TG, responding to the physiological needs (Haugen et al., 
2007; Sethi et al., 2007). In addition, the adipocyte is able to limit an abnormal plasma 
increase of NEFAs (Haugen et al 2007; Lafontan, 2005). The adipose tissue also stores 
cholesterol and fat-soluble vitamins, in particular vitamins D and E (Sethi et al., 2007). 
3.5 Adipose tissue as an endocrine organ 
Previously, it was believed that adipose tissue was a relatively inert tissue primarily 
responsible for the storage of excessive energy in the form of TG (Sethi, Antonio & Vidal-
Puig, 2007). However, beginning in 1994 with the discovery of leptin, a regulator of energy 
homeostasis, it has become clear that adipose tissue is a metabolically active organ (Sethi 
et al., 2007). The white adipose tissue (WAT) is now recognised as an active endocrine 
organ (Fig. 2) that communicates with the brain and peripheral tissues by secreting several 
hormones and protein factors, termed adipokines (Trayhurn, 2005). This term is restricted 
only to the proteins secreted by adipocytes themselves, and this way exclude all the other 
proteins secreted by other cells that exist in WAT such as macrophages (Trayhurn & Wood, 
2004). Over the last 10 years, there have been over 100 different adipokines have been 
discovered and characterised in humans and rodents (German et al., 2010). Adipokines act 
centrally to regulate appetite and energy expenditure, and peripherally affect insulin 
sensitivity, oxidative capacity, and lipid uptake (Gray & Vidal-Puig, 2007). Nevertheless, as 
a dynamic organ, the adipokine profile changes in response to the amount and condition of 
adipose tissue (Gray & Vidal-Puig, 2007).  
Adipokines include classic cytokines (e.g., TNFα, IL-6), antigenic factors, growth factors, 
and proteins involved in vascular homeostasis, regulation of the arterial pressure (eg., 
Angiotensinogen), lipid metabolism, homeostasis of glucose (eg. adiponectin), the 
complement system, as well as proteins of the acute phase and response to the stress 
(Trauhurn & Beattie, 2001; Trayhurn et al., 2004; Haugen et al., 2007).  
One of the most well know adipokines and best characterized in dogs is leptin and it’s 
secretion by the adipocytes is proportional to fat mass, which means in obese individuals 
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plasma levels are higher (regardless of race, gender and age) and decreases with weight 
loss (Considine et al. 1996; Ishioka et al., 2002). Experimentally induced obesity in dogs 
demonstrated that the increased fat mass, with increased BCS, resulted in measurable 
increases in serum leptin and the reduction in fat mass showed the opposite (Ishioka et al., 
2007; Ishioka et al., 2002).  
Leptin acts in multiple centers in the central nervous system (CNS), especially at the 
hypothalamic level (Kershaw & Flier, 2004). The primary action of leptin is to regulate the 
energy balance by decreasing appetite and stimulating energy expenditure (thermogenesis) 
(Rahmouni et al., 2005; Mathieu, Poirier, Pibarot, Lemieux & Després, 2009). Specifically, 
leptin acts on the nervous system to increase satiety (Kershaw et al., 2004). However, in 
obese humans and pets, the higher leptin concentrations do not seem to suppress appetite, 
leading to a hypothesis of leptin resistance (Nishii et al., 2006;  (Vazquez-Vela, Torres, 
Tovar, 2008). Leptin resistance can be explained by several mechanisms, including defects 
in leptin transport across the blood–brain barrier by the saturation of the transport systems 
for leptin (Caro et al., 1996), impaired neuronal leptin signaling in target neurons 
(Munzberg, Flier, Bjorbaek, 2004) or altered signaling in downstream target cells and 
neuro-circuits (Faouzi et al., 2007). This leptin resistance is selective: peripheral leptin 
receptors continue to function and this may be important in the pathogenic metabolic effects 
of hyperleptinemia that occurs in obesity such as the chronic activation of the SNS and 
consequently hypertension that occurs in obesity and will be discussed in chapter III 
(Margetic, Gazzola, Regg, Hill 2002).  
 
Figure 2 - View of the biological function of adipose tissue (represented schematically by a 
single cell), secreting hormones such as cytokines and others. (German et al., 2010a) 
MCP-1 monocyte chemoattractant protein-1; MIF, macrophage migration inhibitory factor; NGF, nerve growth 
factor; IL - interleukin; TNF-a - tumor necrosis factor-a; TGF-b - transforming growth factor-b; PAI-1 
plasminogen activator inhibitor-1; CRP- C-reactive protein; SAA - serum amyloid A  
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4 CLINICAL RISKS ASSOCIATED WITH OBESITY IN COMPANION 
ANIMALS  
In humans, obesity has detrimental effects on health and increases mortality risk (WHO 
2000). The diseases associated with or exacerbated by obesity arise from two 
mechanisms: metabolic changes associated with excess fat and the increase of fat mass 
itself. Obesity is not just a pathological state of overweight, adipose tissue is now 
recognised as an active endocrine organ having local, peripheral and central effects by 
secreting adipokines, as mentioned in the previous section (Trayhurn et al., 2004). On the 
other hand, the increase of fat mass induces physico-mechanical changes  (Osto et al., 
2015; German et al., 2010a; Sandøe, 2014). Like humans, dogs are also susceptible to the 
many and varied health consequences of obesity that we will approach now in the following 
section. 
4.1 Clinical evaluation, physiology 
In general, clinical evaluation is more difficult in an obese dog compared with a dog with 
ideal body condition. Physical examination of an obese patient, namely, chest auscultation, 
abdominal palpation and complementary diagnostic tests, especially ultrasound, are difficult 
to implement due to excess adipose tissue. Blood collection techniques, cystocentesis and 
aspiration of peripheral lymph nodes are also problematic (German, 2006b). 
4.2 Anesthetic risk  
As in obese humans, weight excess affects most vital organs of the obese dog as changes 
occur in cardiovascular, respiratory and metabolic systems (Diez & Nguyen, 2007; Love & 
Cline, 2015). In human medicine, anesthetic drugs are administered according to lean BW 
to avoid over- or under- dosing (Diez et al., 2007; Love et al., 2015). However, the risk 
varies with the type and dose of anaesthetic used and the duration of the surgery (Diez et 
al., 2007; Love et al., 2015). The major risks are an overdose of anesthetic and the 
prolongation of the recovery period due to the storage in body fat of soluble anesthetics in 
the lipids. Obesity has effects on pharmacokinetic (PK) parameters (bioavailability, volume 
of distribution, and clearance) because of the changes in body composition, circulating and 
extracellular volume, organ perfusion, and the compromise on ventilatory capacity (Love et 
al., 2015; Michel et al., 2012). A study performed by Boveri, Brearley, and Dugdale (2013) 
compared the effect of body condition on propofol requirements in dogs and demonstrated 
that overweight dogs required a lower IV propofol dose per kg of total body mass to allow 
tracheal intubation than did normal BCS animals. This suggests that IV anaesthetic doses 
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should be calculated according to lean body mass like humans (Boveri, Brearley & 
Dugdale, 2013). 
Other risks are associated with concomitant disorders, which are common in these patients, 
such as cardio-respiratory disorders (Diez et al., 2007) that lead to an increase in mortality 
after surgery in obese patients (Love et al., 2015). 
4.3 Longevity 
Obesity leads to a reduction in longevity in dogs, as was shown in one study (Kealy et al., 
2002). In the study, 48 Labrador retrievers divided in two randomly selected groups, 24 
dogs for the treatment group and the other 24 for the control group, were used to evaluate 
the effects of 25% diet restriction on the average life expectancy (Kealy et al., 2002). The 
dogs in the group with dietary restriction remained leaner and lived longer; the median 
lifespan was 13 years while the group without restriction was 11.2 years (Kealy et al., 
2002). 
4.4 Endocrine and metabolic diseases 
Several endocrinopathies are associated with obesity, such as insulin resistance in dog and 
humans or diabetes type II in humans (Lund, Armstrong, Kirk & Klausner 2006; 
Mattheeuws, Rottiers & Kaneko, 1984), and hyperlipidemia (Park, Lee & Oh, 2014; 
Jeusette, Lhoest, Istasse & Diaz, 2005).  
Pancreatic βcells, in the Langerhans islets, are responsible for the secretion of insulin, 
which manages uptake and use of glucose in peripheral tissues (Michel et al., 2012). In 
humans, the constant excess of calories ingested leads to decreased tissue sensitivity to 
insulin (i.e. become ‘insulin resistant’) (Michel et al., 2012; German, 2006b). There is a 
positive correlation between plasma concentrations of insulin and BMI in humans (Michel et 
al., 2012; German, 2006b). In overweight dogs this obesity-induced insulin resistance and 
hyperinsulinemia has also been reported (Gayet et al., 2004). However, the degree of 
insulin resistance associated with diet-induced obesity appears to be dependent on age, 
with older dogs being more insulin-resistant than young dogs (Serisier et al., 2008a). 
Weight-loss leads to a recovery of insulin sensitivity and decreased insulin concentrations 
(Diez et al.,, 2004; Yamka et al., 2006a). Contrary to obese humans, insulin resistance in 
obese dogs does not spontaneously progress to type II diabetes mellitus (Verkest, 
Fleeman, Rand & Morton, 2011; Verkest, Fleeman, Rand & Morton, 2012).   
Beside insulin resistance, obesity is one of the principal causes of hyperlipidemia in dogs. 
Even with moderate obesity the levels of serum triglycerides and total cholesterol are higher 
than lean dogs (Pena, Suarez, Bautista, Montoya & Juste, 2008; Jeusette, et al., 2005). 
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Both alterations are reversed by weight loss (Jeusette et al., 2005). The long-term effects of 
hypertriglyceridemia observed during obesity have been associated with an increased risk 
of acute necrotizing pancreatitis in humans (Kota & Jannula, 2012).  For dogs this 
association has been proposed as a risk factor for pancreatitis, however, further studies 
have to be performed to assess cause and effect relationships (Osto et al., 2015, Weeth, 
2016). 
4.5 Cardiorespiratory changes and systemic hypertension 
Obese dogs have an increased prevalence of cardiovascular disease in the form of 
congestive heart failure (Edney et al., 1986). The adverse effects of obesity on left 
ventricular function can be explained by three mechanisms: an increased plasma volume 
which increases ventricular preload, hypertension that raises left ventricular afterload, and 
alterations in the myocardial genome that result in systolic and diastolic dysfunction (Diez & 
Nguyen, 2010; German, 2006b; Diez et al., 2007). Increased blood pressure has been 
documented in overweight and obese dogs (Bodey & Michell, 1996; Montoya et al., 2006; 
Mehlman, et al., 2012). The largest study of blood pressure in dogs to date showed that the 
obesity effectively increases the blood pressure, however this increase was small (5 
mmHg), and insufficient to lead to clinical consequences (Bodey et al., 1996).  Another 
early study showed similar alterations (Remillard, Ross, Eddy & 1991). The American 
College of Veterinary Internal Medicine (ACVIM) has considered the effects of obesity on 
blood pressure as small and the prevalence of hypertension as very low (Brown et al.,, 
2007.). However, obese dogs have left ventricular hypertrophy (Mehlman et al., 2012), 
which is reversible with weight loss (Neto, Brunetto, Sousa, Carciofi & Camacho, 2010.; 
Pelosi, Rosenstein, Abood & Olivier, 2013).  
Obesity can also exacerbate, aggravate or be responsible for several respiratory diseases. 
The most notable examples are laryngeal paralysis and brachycephalic airway obstruction 
syndrome that are aggravated by obesity (German, 2006b; Diez et al., 2007; White & 
Williams, 1994). Obesity also exacerbates heatstroke and there is a high risk of tracheal 
collapse development in dogs (German, 2006b). The main symptoms in obese patients are 
exercise intolerance and shortness of breath (Toll et al., 2010). 
4.6 Traumatic and degenerative orthopaedic disorders 
Dogs with overweight have a high risk to develop traumatic and degenerative orthopedic 
disorders (Edney et al., 1986; Michel et al., 2012; German, 2006b). There is a greater 
osteoarthritis (OA) severity in dogs with BCS above ideal (Toll et al., 2010). An 
improvement of OA in obese dogs was demonstrated with weight loss of 6.1% onwards, 
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with a decrease of lameness (Marshall et al., 2010). The mechanical stress due to the 
weight increase appears to be the major factor associated with this relationship and to be a 
predisposing factor in humeral condylar fractures, cranial cruciate ligament rupture and 
herniated disc (Case et al., 2000; German, 2006b). Because there is also a strong 
association between obesity and severity of OA in others joints such as the hand joint in 
humans that are not a mechanically stressed, it has been questioned whether obesity has 
only a strictly mechanical impact (Frye, Shmalberg & Wakshlag, 2016). These findings led 
to further interest in the inflammatory mediators released from adipose tissue (e.g., 
cytokines IL-6 and TNF-a, and the adipokines leptin, visfatin, adiponectin, and resistin) 
(Frye et al., 2016). A recent study in humans, was performed to find the role of BW in the 
pathogenesis of osteoarthritis (OA) and the results have suggested that obese adipokine 
concentration, mainly the adiponectin, in synovial fluid may contribute to the metabolic 
changes associated with OA (Gross, Guillaume & Gegout-Pottie, 2014). However, which 
adipokines and their exact role in osteoarthritis are still unclear (Frye et al., 2016). In dogs 
there is paucity of information about the relationship of adipokines with osteoarthritis, and 
unlike in people, would be even more difficult because all major affected joints are weight 
bearing (Frye et al., 2016)..  
Besides the fact that orthopedic problems can be cause by obesity, these orthopaedic 
disorders alone predisposes these individuals (humans and dogs) to be less active, which 
is a risk factor for obesity and thus requires an adaptation of energy intake in order to 
prevent overeating and excess weight and avoid the aggravation of the pathology (Michel et 
al., 2012; Toll et al., 2010; German, 2006b). 
4.7 Effects on renal function and urinary tract disorders  
In humans, obesity is known as a risk factor for CKD due to the fact that prolonged obesity 
can cause structural and functional changes in the kidney (e.g., greater kidney weight, 
higher plasma renin activity and insulin concentration, high arterial pressure and high GFR, 
an expanded bowman´s capsule, increased mesangial matrix, and increased thickened 
glomerular and tubular membranes (Chang, Ryu & Choi, 2016; Zhang & Lerman, 2015; 
Griffin et al., 2008). In a prospective cohort study with 62,249 metabolically healthy persons 
performed by Change the risk for CKD the results demonstrated that persons with BMI of 
overweight and obese (23 to 24.9 kg/m2, and 25 kg/m2 or greater, respectively) were 
associated with an increased incidence of CKD, with an incidence rate of 2.9 cases per 
1000 person-years for overweight and 3.6 for obese compare with the 2.1 for normal weight 
(Chang et al., 2016). 
In dogs, experimentally induced obesity resulted in increased arterial pressure (+12 +/- 3 
mmHg) and high levels of plasma renin activity, which can alter the renal function and 
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cause histologic changes in the renal architecture like in humans (Heneger, Bigler, 
Heneger, Tyagi & Hall 2001). This study performed by Heneger in 2001 demonstrated that 
obese dogs had insulin concentrations 2.3 fold greater compared with lean dogs as well as 
significantly larger glomerular Bowman's space area (+41 +/- 7%), mainly because of 
expansion of Bowman's capsule (+22 +/- 7%) (Heneger et al., 2001). GFR was 38 +/- 6% 
greater and the renal plasma flow was also 61 +/- 7% higher than the lean dogs (Heneger 
et al., 2001). Cell proliferation in glomeruli, thickening of glomerular and tubular basement 
membrane, and increased mesangial matrix were also observed (Heneger et al., 2001). 
The concentration of biomarkers of renal injury (homocysteine, cystatin, and clusterin) also 
improved after weight-loss in client-owned dogs (Tvarijonaviciute et al., 2013). This issue 
will be deeply explained further ahead in part II, section III. 
In addition to this problem, obesity in humans is also associated with a higher incidence 
and prevalence of nephrolithiasis (Scales, Smith, Hanley & Saigal, 2012; Taylor, Stampfer 
& Curhan, 2005). Increased BW is associated with lower urinary pH and increased 
excretion of urinary oxalate, uric acid, sodium and phosphate (Maalouf, Sakhaee, Parks, 
Coe, Adams-Huet, Pak, 2004; Lemann, et al., 1996). Other studies have shown that obesity 
may increase the risk of renal cancer, however, it is unclear (Calle & Kaaks, 2004). 
In dogs, a study by Lekcharoensuk et al. (2000) reports that dogs classified as overweight 
had 2 times greater risk for developing nephrolithiasis (calcium oxalate), compared with 
dogs that were ideal in BW (Lekcharoensuk, et al., 2000). Overweight dogs also have an 
increased risk of developing transitional cell carcinoma of the bladder (Glickman, Schofer & 
McKee, 1989). 
4.8 Neoplasms 
In humans, there is some evidence that obesity is a risk factor for neoplasia (Lund et al., 
2006). In vitro studies already showed that elevated leptin is a promoter of mammary 
tumors and hepatocellular carcinomas (Zou & Shao, 2008). According to Alenza, Rutteman, 
Pena, Beynen & Cuesta (1998), obesity in juvenile female dogs plays an important role in 
predisposition to mammary tumors in adulthood. Also in obese humans there are elevated 
levels of leptin, IL-6, resistin and TNF- α, which inhibit normal apoptotic mechanisms and 
promote angionesis which may promote cancer (Yin, Wang & Zhang, 2004). However, in 
dogs is not possible yet to associate this relationship between adipokines and 
tumorigenesis or associate a specific cancer to obesity because there is not enough data 
yet (Weeth, 2016). 
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5 PATHOPHYSIOLOGY OF OBESITY 
The reasons for obesity are not completely evident as there are a huge number of factors 
that can cause this situation, but the major cause is an imbalance between energy intake 
and expenditure (Sandøe et al 2014; Loftus & Wakshlag, 2015; German, 2006b). According 
to Loftus et al. (2015), the major factors involved can be divided into two: factors that affect 
energy metabolism, such as resting metabolic rate, active metabolic rate, and relative 
activity, and those that affect energy intake and assimilation, such as the behavior of 
eating/feeding (hormonal and behavioral), the factors in food that affect nutrient assimilation 
or/ and the digestion efficiency.  
Next, a small part of the pathophysiology of obesity that includes the principles of energy 
balance and the physiological regulation of BW will be discussed as well as the main risks 
factors that can contribute to obesity. 
5.1 Energy balance 
The fundamental principle of energy balance is as follows: changes in energy stores = 
energy intake - energy expenditure.  According to this principle, positive energy balance 
occurs when energy intake exceeds expenditure, and consequently results in energy 
storage and weight gain  (Diez & Nguyen, 2010; Toll et al., 2010; Michel et al., 2012). 
Contrarily, negative balance is when the expenditure exceeds intake. Though, in the long 
run, in a state of BW maintenance, energy intake matches energy expenditure regardless of 
the natural oscillations that occur everyday (Backus & Wara, 2016). A lot physiologic 
mechanisms have a relevant role in adapting intake to expenditure and vice versa, so as to 
keep a stable BW over the long term (Backus et al., 2016). There is an energy expenditure 
increase when energy balance is positive. This increase happens through the release of 
heat at the expense of ATP. On the other hand, when the energy balance is negative, 
there’s a decrease of energy expenditure, which consequently helps to resist weight loss 
(Diez & Nguyen, 2010).  
The total energy expenditure can be split into three components: resting energy 
requirement (RER), physical activity and the postprandial thermogenesis (Diez & Nguyen, 
2010; Toll et al., 2010). Total energy expenditure varies according to the regularity and 
intensity of physical activity, the most variable component (Backus et al., 2016). In one dog, 
the RER usually represents between 55% and 70%, the physical activity between 30% and 
40% and the postprandial thermogenesis 10% of the daily energy requirements (Toll et al., 
2010). 
RER is the quantity of energy that a dog requires to maintain normal physiologic functions 
at rest (Toll et al., 2010; Michel et al., 2012). Physiological functions are determined by lean 
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mass, which represent 90-95% of RER versus 5-10% of fat mass (Michel et al., 2012; Diez 
& Nguyen, 2006; Diez & Nguyen, 2010).  
The postprandial thermogenesis represents the production of heat associated with 
ingestion, digestion, assimilation, and metabolism of food and is influenced by the 
nutritional and caloric composition of the food, the number of meals per day and the 
nutritional status of the animal (Michel et al., 2012; Toll et al., 2010; Case et al., 2000). 
Physical activity represents the movement produced by skeletal muscle contraction that 
results in an increase in energy expenditure (Backus et al., 2016). This last component may 
represent an important factor for the management of obesity. 
5.2 Physiological regulation of body weight 
Most dogs maintain an ideal, constant BW due to a biologic and complex set of neural, 
hormonal and biochemical mechanisms that keep the balance between energy intake and 
expenditure within fairly precise limits (Druce & Bloom, 2003). This physiologic mechanism 
that stabilizes BW are complex and still poorly understood (Backus et al., 2016). A small 
part of this mechanism is the control of food intake, which regulates BW (Losada, 2005). 
Food intake is, according to Backus et al. (2016) a conditioned behavior compelled by 
motivations to initiate or terminate a meal. These motivations are regulated by a feedback 
system with afferent and efferent mechanisms, which continually receive and send 
information to the central nervous system that give order to eat and not to eat (hunger and 
satiety) (Backus et al., 2016). The afferent system is divided in the sensory signals such as 
appearance, odor, and taste (Miján de la Torre, 2004; Losada, 2005). The others are 
signals from the digestive tract such as stretch and chemoreceptors that provides satiation 
feedback (Backus et al., 2016). Later post-ingestive signals (e.g., increased insulin, 
decreased glucagon) additionally serve as satiation feedback affecting meal termination 
(Backus et al., 2016). These signals reach the central nervous system through peripheral 
innervations. The stimulation of the hypothalamus regulates the food intake through two 
centers: hunger center and satiety center (located in the ventromedial nucleus) (Losada, 
2005). The hypothalamus plays a major role in regulating energy homeostasis: it integrates 
peripheral, neural and hormonal afferent signals of satiety and energy reserve, directing 
efferent signals that affect either energy storage or energy expenditure (Backus et al., 
2016). 
Beside this factor adiposity signals also affect food intake (Backus et al., 2016). There is an 
internal mechanism that measures amount of body fat and in turn acts to adjust food intake 
in accord with the amount of energy needed to maintain a set-point in body fat (Backus et 
al., 2016). A most clearly agreed on adiposity signal is plasma concentration of a protein 
called leptin, one of the most known hormones in obesity, is produced by adipose tissue in 
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proportion to its reserves in fat mass (Miján de la Torre, 2004, Considine et al., 1996). It 
acts on the satiety centers of the hypothalamus and is responsible for modulating an activity 
of several effector neuronal systems and axonal pathways, resulting in decrease of food 
intake and energy expenditure increases when the level of leptin are high and vice-versa 
(Miján de la Torre, 2004; Backus et al., 2016). 
Insulin concentration in plasma is also considered by some investigators to be an adiposity 
signal (Porte & Woods, 1981). Although insulin is a hormone principally secreted by 
pancreatic endocrine cells and not adipose, concentrations of insulin rise in plasma with 
increasing body fat in dogs (Porte et al., 1981). A feedback role for insulin is that it crosses 
the blood-brain barrier, and it bind to receptors on the neural circuit that affect the food 
intake, and by intracranial insulin infusions at physiologic doses reduce food intake (Porte 
et al., 1981; Woods & Begg, 2015). When adiposity increases, the average circulating 
insulin concentration rises because of a resistance of insulin (Hoenig, Thomaseth, Waldron 
& Ferguson, 2007). Research in dogs indicates such insulin resistance could result from 
diminished transport of peripheral insulin to the brain (Hoenig et al., 2007). This high 
plasma insulin in obesity could be a braking signal functionally preventing further undesired 
gain in adiposity from continued overeating (Woods et al., 2015).  
5.3 Risk factors 
Although the pathophysiologic mechanisms responsible for the development of obesity are 
complex and multifactorial, one must also consider the individual components that can 
impact physical activity and the energy expenditure (Backus et al., 2016). Age is one of 
these factors. The frequency of obesity in dogs increases with age (Robertson, 2003; 
Colliard, Ancel, Benet, Paragon & Blanchard, 2006). Throughout the animal's adult life the 
energy requirements reduces as well as the quantity of lean mass that results in a reduction 
of the daily energy requirements (Speakman, Van Acker, Harper, 2003). The frequency of 
obesity in animals with less than 2 years old is low and after that age the frequency 
increases; the age of diagnosis is between 5 and 8 years (more than 50% are between 7-8 
years and approximately 70% are over 9 years old) (Armstrong & Lund, 1996). Another 
factor can be the type of breed because some breeds (e.g., Labrador retriever, Boxer, Cairn 
King Charles Spaniel, Cocker Spaniel, Beagle) are predisposed to obesity, and may be 
likely a genetic factor as is the case of the pro-opiomelanocortin (POMC) gene in Labrador 
retrievers. Raffan et al. showed that a frame-shift deletion mutation in POMC is strongly 
associated with weight, adiposity, and appetite and also in flat-coat retriever (FCR) dogs 
(Raffan, et al. 2016; Zoran, 2010; German, 2006b; Edney et al., 1986).  
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Lack of exercise can be another factor and one of the principal factors in the development 
of obesity due to a reduced total energy expenditure and RER, and a decrease in lean body 
mass (LBM)  (Diez & Nguyen, 2010).  
Some endocrine diseases can be associated with obesity too, such as hypothyroidism, and 
may also be secondary to hyperadrenocorticism (Diez & Nguyen, 2010).  Hypothyroidism 
results in reduced energy needs at rest, which in turn may predispose to obesity. In 
hyperadrenocorticism there is an overproduction of corticosteroids by the adrenal cortex, 
which induce hyperphagia and secondarily overweight (German, 2006b). Also some drugs, 
such as glucocorticoids and anti-epileptic drugs, induce hyperphagia and secondarily 
overweight (Elliott, 2006b).  
Gonadectomy is known for raising the risk of obesity in dogs (Edney et al., 1986; 
Robertson, 2003; McGreevy et al., 2005; Colliard et al., 2006). One study of the prevalence 
of obesity in dogs performed in Australia by McGreevy et al. (2005) demonstrated that 8.7% 
of sterilized females are obese vs. 5.3% intact obese females; 9.5% of castrated males are 
obese vs. 3.2% intact obese males. Neutering affects the food intake, which could be due 
to the withdrawal of the gonad steroid hormones, estradiol and testosterone (Backus et al., 
2016). A study demonstrated that after of ovariectomy, the daily energy requirement 
decreased 30% in bitches (Jeusette, Detilleux, Cuvelier, Istasse & Diez, 2004). In a study 
conducted by Houpt, Coren, Hintz & Hilderbrant (1979), ovariohysterectomized bitches 
increased their weight significantly in the first 10 postoperative days, and also the food 
intake, compared to the control group. The lost of estrogens and androgens also seems to 
decrease the metabolic rate and decrease of physical activity that might occur due the 
decreased sexual behaviour and roaming (Toll et al., 2010; Zoran, 2010; German, 2006b). 
There another factor that can contribute is the way of feeding (the quantity or how it is 
offered) or specific characteristic of foods such as palatability and energy density. For 
example, high-fat diets have lower satiating power than high protein low-fat diets and can 
increase the risk of obesity (Gerstein, Woodward-Lopez, Evans, Kelsey, Drewnowski, 2004; 
Kaiyala, Prigeon, Kahn, Woods, Schwartz, 2000). An epidemiological study indicated that 
dogs fed once a day are heavier (Kienzle, Bergler, Mandernach, 1998; Robertson, 2003). 
Also, the offering of treats and food leftovers are considered risk factors by Robertson 
(2003). Because humans have a tendency to humanize their pets and communicate 
through food, owners consequentially end up overfeeding their animals contributing to 




III. Physiopathology Relationship Between Obesity and Renal Insufficiency 
1 RENAL FUNCTION AND ASSESSMENT 
The kidneys are essential for the maintenance of organism homeostasis (Joazeiro, 2008). 
They perform several functions, among them are the clearance of toxins of the metabolism 
or foreign substance, regulation of fluid balance, maintenance of acid-base, regulation of 
sodium, potassium and other electrolytes, regulation of blood pressure, and production of 
various hormones, such as erythropoietin (Verlander, 2014). 
All these functions are performed by the functional unit of the kidney, the nephron, which 
consists of two distinct anatomical and functional structures, glomeruli and tubules 
(Verlander, 2014). As it crosses the glomeruli, the blood arriving through the afferent 
arteriole loses a filtrate which is essentially protein-free, which travels through the tubules 
and is modified by excretion and reabsorption performed by tubular epithelial cells 
(Verlander, 2014). Thus, the nephron performs three successive physiological acts, 
glomerular filtration, tubular reabsorption and tubular excretion, with the end product being 
urine (Verlander, 2014). Urine contains most of the body's metabolites, which are 
eliminated in varying amounts along with water (Verlander, 2014). As the amount of nefrons 
decreases, the renal function could be impaired and renal insufficiency develops. Renal 
insufficiency occurs when there are approximately 75% of functional nephrons damaged 
(Verlander, 2014). When renal insufficiency occurs the kidneys are not able to maintain 
their normal functions of regulation, excretion and also endocrine functions (DiBartola, 
2010). This incapacity results in retention and accumulation of uremic toxins and an 
imbalance on the acid-base and on the equilibrium of chemical electrolytes (DiBartola, 
2010). Clinically it is defined by the presence of azotemia, characterized by high 
concentrations in blood of toxic compounds such as urea and creatinine, and by decreasing 
the concentration of urine, resulting in hyposthenuria (DiBartola, 2010). 
Evaluation of glomerular filtration rate (GFR) is considered the gold standard and most 
sensitive test to evaluate renal function (Heiene, Lefebvre, & Watson, 2015). GFR 
describes the flow rate of filtered fluid. Several methods for measuring GFR have been 
validated in dogs, including plasma clearance techniques using non-radioactive markers 
such as creatinine and iohexol (Heiene et al., 2015). A decrease in GFR beyond the normal 
range means that kidney function is deteriorating and also allows to evaluate the  severity 
and the progression of renal diseases, especially chronic kidney disease (CKD) (Heiene et 
al., 2015). However, is considered impractical in most veterinary clinics because it requires 
repeated blood sampling over a period of several hours following intravenous administration 
of a suitable marker (Heiene et al., 2015).  
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In the clinical practice serum concentrations of blood urea nitrogen (BUN) and creatinine 
are the most commonly used tests for indirectly estimating GFR (Verlander, 2014). Urea 
excretion occurs by glomerular filtration in the kidney, and BUN concentrations are 
inversely proportional to GFR (DiBartola, 2010). However, urea can be influenced by 
several conditions such as dehydration, the diet, and clinical conditions characterized by 
increased catabolism (e.g. starvation, infection, fever) (DiBartola, 2010). Because of all 
these non-renal variables, BUN alone is poor as an indicator of GFR (DiBartola, 2010). 
Creatinine excretion is accomplished almost exclusively by glomerular filtration, and is not 
significantly reabsorbed or secreted by the renal tubules (Heiene et al., 2015). Its 
concentrations have an inverse relationship with GFR, which means, when GFR decreases, 
creatinine serum increases (Heiene et al., 2015). An advantage of this marker is it is less 
influenced by feeding than BUN concentration (DiBartola, 2010). However, it may be 
affected by breed and body size (Gleadhill, 1995).  
The usefulness of BUN combined with serum creatinine is a very useful clue to the 
presence of a prerenal or postrenal component to azotemia (DiBartola & Westropp, 2014). 
When there is a high BUN/creatinine ratio the clinician should begin a search for extrarenal 
factors such as high protein intake, that increases urea but can maintaine the creatinine 
concentration, or gastrointestinal bleeding or also catabolic states as fever (DiBartola & 
Westropp, 2014). A low BUN/creatinine ratio suggests inadequate protein intake and 
reduced urea synthesis as in advanced liver disease (DiBartola & Westropp, 2014). BUN 
and creatinine, taken together, are valuable screening tests in evaluating renal disease 
(DiBartola & Westropp, 2014). Though they may fall short as absolute indicators of renal 
function, they are useful in following progression of disease (DiBartola & Westropp, 2014). 
Another renal marker important for assessing renal function is evaluating the presence of 
proteinuria. Persistent proteinuria with inactive urine sediment is associated with CKD as 
well as with its progression. The greater the magnitude of proteinuria is, the greater the risk 
of renal disease progression and mortality (Jacob et al., 2005; Lees, Brown, Elliot, Grauer, 
Vaden, 2004). Proteinuria is defined as the presence of any type of protein in the urine, 
such as albumin, globulins, and Bence Jones proteins (Gregory, 2013). Clinical significance 
of proteinuria depends on its severity and persistence. In the absence of hyperproteinemia, 
hematuria and urinary tract inflammation, persistent proteinuria usually indicates kidney 
disease and severe proteinuria is associated with glomerular disease (Jacob et al., 2005). 
Proteinuria of renal origin results of a loss of selective glomerular filtration resulting in an 
increased amount of plasma protein in the filtrate or an impaired reabsorption of the filtered 
protein, which can happen without an initial substantial decrease in the number of functional 
nephrons (Gregory, 2013).  
Other marker that can be an indicator of kidney dysfunction is the ability to concentrate 
urine. Loss of concentrating ability can be one of the earliest indicators of kidney 
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dysfunction, which is generally recognized when two-thirds of nephrons are non-functional 
(Forrester et al., 2010). In CKD, the renal interstitial osmolality gradient is decreased 
because of increased urine flow per nephron or because of inability to establish and 
maintain the medullary concentration gradient (Forrester et al., 2010). 
The challenge is try to find ways to recognize kidney diseases earlier in their course, before 
clinical signs are evident, to permit institution of any available measures (prevention, 
treatment or monitoring) that might slow progression of the disease and prevent 
development of complications. This is why novel early biomarkers (for example serum 
cystatin C and SDMA concentrations) of CKD are being researched because the routine 
renal markers used in practice are insensitive for early diagnosis (Hall, Yerramilli, Obare, 
Yerramilli & Jewell, 2014). 
Accompanying the incidence of obesity in recent years, several studies have been 
conducted investigating the repercussions of this disease on the functioning of various 
organ systems, including the kidney, that will be approach next (Joazeiro, 2008). 
2  “HIDDEN EPIDEMIC” 
In humans, obesity is a potential risk factor for the development of kidney disease because, 
as previously described, it increases the risk of developing major risk factors of CKD, such 
as diabetes type II and hypertension (WHO, 2017; Kovesdy, Furth, Zoccali, 2017). 
Numerous studies have shown an association between obesity and both the development 
and the progression of CKD (WHO, 2017; Kovesdy et al., 2017). The first reports on a 
possible relationship between obesity and renal dysfunction date back to 1970s, when 
Weisinger et al. proposed that the cause of reversible proteinuria in obese patients is renal 
venous hypertension (Weisinger, Kempson, Eldridge, Swenson, 1974).  
In 2001, Kambham et al. published an extensive review with findings of 6618 biopsies in 
humans, in which they found a 10-fold increase in the incidence of nephropathy secondary 
to obesity, from 0.2% in the period 1986-1990 to 2% in 1996-2000 (Kambham, Markowitz, 
Valeri, Lin & D'Agati, 2001). This data was confirmed by Chen et al. (2004), who identified a 
strong association between obesity-related CKD and to microalbuminuria (Chen et al., 
2004). Moreover, individuals affected by obesity have an 83% increased risk of developing 
CKD (Kovesdy et al., 2017). Data also revealed that there is a difference in gender as well, 
24.9% of women with CKD were associated with overweight or obesity while in men it was 
13.8% (Kovesdy et al., 2017). Furthermore, an association between BMI and CKD was 
found even independent of other pathologies associated with obesity (diabetes type II, 
systemic arterial hypertension). The higher the BMI was, the greater the risk of developing 
CKD, which led many authors to attribute obesity by itself in the role of inducing of renal 
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injury (Chang et al., 2013; Foster et al., 2008; Praga et al., 2000). In large human 
population-based studies, higher BMI is associated with low estimated GFR, with more 
rapid loss of estimated GFR over time and with higher incidence of ESRD (Pinto-Sietsma, 
et al., 2003; Ejerblad et al., 2006; Foster et al., 2008). Higher BMI was also associated with 
the presence and development of proteinuria in individuals even without kidney disease 
(Foster et al., 2008). Other studies described an association between higher abdominal 
girth and albuminuria, decreased GFR or incident ESRD independent of BMI level (Kramer 
et al., 2016; Thoenes et al., 2009). In general, the associations between obesity and renal 
disease persist even when the common effects associated with obesity are absent, such as 
high blood pressure or diabetes mellitus, which suggest obesity has a independent impact 
on kidney unrelated to these complication (Kovesdy, et al., 2017). 
In ours pets, the few data on obesity and renal insufficiency that exist do not allow us to 
make an association between obesity and renal dysfunction as in humans. However, 
studies in experimental dogs show similar findings with regard to obesity-related renal injury 
(Heneger et al., 2001). The incidence of obesity has also been increasing in our pets, as 
was previously discussed, so one can speculate that the incidence of kidney disease may 
also be increasing due to obesity. 
3 PATHOPHYSIOLOGY OF OBESITY-RELATED RENAL DISEASE   
The first sign of renal injury secondary to obesity is the increase of proteinuria or 
albuminuria, caused mainly by glomerular hyperfiltration, or renal venous hypertension 
(Chang et al., 2013; Foster et al., 2008; Praga et al., 2000). According to Chagnac et al. 
(2003), weight loss improves glomerular hemodynamics (Chagnac et al., 2003). Morales et 
al. (2003) evaluated two groups of human patients (randomly assigned in a 2:1 ratio) of 30 
overweight with diabetic and nondiabetic proteinuric nephropathies, to either follow a low-
calorie normoproteinic diet or maintain their usual dietary intake for 5 months.  (Morales, 
Valero, León, Hernández & Praga, 2003). At the end of five months, they found that the 
group with the low-calorie normoproteinic diet loss 4.1%, which result on a reduction of 31% 
on proteinuria by reducing hyperfiltration secondary to obesity, reinforcing the effects of 
overweight on glomerular function, even with a moderate weight loss (Morales et al., 2003). 
Furthermore, the evaluation the renal structure by biopsy identified an association of 
obesity-related glomerulopathy (ORG) with the occurrence of sclerosis and hypertrophy in 
the glomerular region, which are an important causes of and contributors to CKD 
(Kambham et al., 2001).  
The studies in obese dogs seem to show a similar relation as in humans. Experimentally 
induced obesity in dogs fed a high-fat diet showed higher mean arterial pressure and 
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plasma renin activity, an increase of glomerular filtration rate and also histological changes 
(expansion of Bowman's capsule, increased mesangial matrix, thickening of glomerular and 
tubular basement membranes, and increased cell proliferation in the glomerulus) when 
compared to lean control group (Henegar et al., 2001). An inverse study performed with 
obese pet dogs that lost between 10-40% of their BW had evidence of improved renal 
function, with increased urine specific gravity, decreased UPCR and decreased serum 
creatinine (Tvarijonaviciute et al., 2013).  
Although there is currently a consensus among researchers that obesity contributes to renal 
impairment, the mechanisms by which these disorders limit organ function have not yet 
been fully elucidated. Two possible pathways may mediate these deleterious renal 
consequences of obesity. The first pathway, the indirect effects on the kidney, include 
effects from coexisting conditions such as diabetes, or hypertension, both of which are the 
most common cause of CKD and of which it is recommended for CKD screening (Kovesdy 
et al., 2017; Hall et al., 2014; Griffin et al., 2008). The second pathway, the direct effects on 
the kidney, is the adiposity effect (Kovesdy et al., 2017; Hall et al., 2014; Griffin et al., 
2008). Some hypotheses that have been explored are the compressive effect of visceral 
adipose tissue on the renal parenchyma; the activation of the sympathetic nervous system 
(SNS) and the activation of the renin angiotensin aldosterone system (RAAS) (Kovesdy et 
al., 2017; Hall et al., 2014; Griffin et al., 2008). In next sections, how adipose tissue can 
interacts with normal renal function, as well as the possible mechanisms by which obesity 
may contribute to the development of hypertension, renal dysfunction and eventually CKD 
will be discussed. 
3.1.1 Physical compression of the kidneys 
In humans and dogs, excess visceral fat is associated with an increase of intra-abdominal 
pressure (Kopple & Feroze, 2011; Kopple, 2010; Bloomfield, Sugarman, Blocker, Gehr & 
Sica, 2000) reaching levels as high as 35 to 50 mm Hg in some dogs with central obesity 
(Sugarman et al., 2000). In dogs an increase of intra-abdominal pressure by 25 mm Hg for 
4 weeks produced a 28 mm Hg rise in arterial pressure (Bloomfield et al., 2000). The kidney 
is a retroperitoneal organ surrounded by the perirenal space and pararenal anterior and 
posterior space, which are occupied by fat that extends into the renal sinus and penetrates 
to the medulla (Verlander, 2014). Due to the low complacency of the renal structures, 
increased amount of fat in this space act as compressive forces on the capsule, causing an 
increase of hydrostatic pressure and renal interstitial fluid (perinephric hypertension) 
(Bloomfield et al., 2000; Sugarman, Windsor, Bessos & Wolfe 1997). The increased 
intrarenal pressure, in turn, compresses the loop of Henle and the peritubular capillaries 
(vasa reta), which reduces the flow through the renal tubules, leading to an increased 
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tubular reabsorption of sodium (Bloomfield, et al., 2000; Kopple, et al., 2010; Hall et al., 
2004). This increase of sodium reabsorption is accompanied by a compensatory renal 
vasodilation and an increase in GFR to maintain the sodium balance in obese individuals 
(Chagnac et al., 2000; Xu et al., 2017). However, other mechanisms responsible for the 
increase in GFR in obese individuals are not fully elucidated. Some evidence suggests that 
it may be mediated primarily by the macula densa feedback mechanism. Macula densa 
cells sense changes in sodium chloride level, and will trigger an autoregulatory response 
(Verlander, 2014). When there is a drop in salt concentration, macula densa cells responds 
through two mechanisms: First, it triggers dilation of the renal afferent arteriole, decreasing 
afferent arteriole resistance and, thus, offsetting the decrease in glomerular hydrostatic 
pressure caused by the drop in blood pressure; second, macula densa cells release 
prostaglandins, which trigger granular juxtaglomerular cells lining the afferent arterioles to 
release renin into the bloodstream (Verlander, 2014). This could explain why obesity is 
associated with a reduction on afferent arteriolar resistance and increases in renal blood 
flow, GFR, and stimulation of renin release (Hall et al., 2003). In chronic obesity this 
compensatory mechanism (renal vasodilation, glomerular hyperfiltration plus the increases 
in arterial pressure with increase glomerular wall tension) may cause renal injury, 
glomerulosclerosis, and ultimately nephron loss with a decline of GFR (Xu et al., 2017; 
Kovesdy et al., 2017; Hall et al., 2014; Hall, et al., 2004). 
3.1.2 Lipotoxicity 
Despite the physical effect that obesity exerts on the renal parenchyma, ectopic deposition 
of lipids into non-adipose tissues, such as the kidney, often occurs in obesity (Hall et al., 
2014). This is associated with the disorders caused by the exacerbated metabolism of fatty 
acids in non-fatty tissues, such as skeletal muscle, pancreatic islets, myocardium and 
kidneys and results in lipotoxicity (Kopple, et al., 2010; Jeanne & Sturley, 2009). Lipotoxicity 
is an accumulation of lipid intermediates in non-adipose tissue, leading to cellular 
dysfunction and induce apoptosis (Kopple, et al., 2010; Garbarino et al., 2009). Studies 
have previously documented that the deposition of adipose tissue at the abdominal level 
leads to an increase in the concentration of circulating non-esterified fatty acids (NEFAs) 
(Bjorntorp, 1990). At the liver level, NEFAs stimulate VLDL production, which will transport 
large amounts of triglycerides to various peripheral tissues, including the kidney (Bjorntorp, 
1990). At the intracellular level the triglycerides are stored as lipid droplets (de Vries et al., 
2014; Weidemann & Krebs 1969). Inside of the cell, lipids are not neutral or inert and the 
accumulation of toxic metabolites derived from their metabolism, such as diacylglycerols or 
ceramides, can lead to important cellular alterations such as mitochondrial dysfunction and 
endoplasmic reticulum stress (Weidemann et al., 1969; Unger & Orci, 2000; de Vries et al., 
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2014). These changes lead to a decrease in the ability to oxidize the NEFAs and 
consequently to their accumulation (Unger et al., 2000). On the other hand, the NEFAs 
participate in all phases related with glucose metabolism, from use by tissues to the 
production and storage in liver (Savage, Petersen, Shulman, 2007). These deregulations 
(accumulation of toxic metabolites, decrease ability to oxidize NEFAs and their 
accumulation on tissues) inhibit the entry of glucose in the tissues, and is inversely 
correlated with the level of insulin sensitivity (Savage et al., 2007).  
This ectopic deposition of lipids into non-adipose tissues has been associated with CKD. 
Renal biopsies of humans with obesity-related glomerulopathy demonstrated extensive 
accumulation of lipids in mesangial cells, podocytes and tubular cells, which was 
associated with clinically significant metabolic changes, such as insulin resistance (Straub 
et al., 2013). There is evidence in animal models that explain how excess renal lipids are 
related with renal injury and consequently ORG. Studies focus mainly on the effect of 
intracellular lipid accumulation on the different constituents of the renal parenchyma, such 
as the mesangial cells that lose their contractility capacity, or the podocytes that seems to 
be a stimulus for apoptosis, or a poorly adaptive response in the remaining podocytes (de 
Vries et al., 2014; Chen, Liu, Zeng, Li, Wang, 2006; Bobulescu, 2010). In dogs, we are not 
aware of a similar study. However, there are studies that showed lipotoxicity in other 
organs, such as the investigation performed by Adolphe et al in 2014 that used  computed 
tomography to show that the increments of visceral adipose tissue during weight gain is 
more strongly correlated with metabolic and cardiovascular (increased of systolic left 
ventricular free wall thickness) alterations than with subcutaneous fat, that occur within only 
12 weeks of obesity in an obese dog model (Adolphe, Silver, Childs, Drew & Weber 2014). 
They also showed that fasting serum glucose concentrations increased significantly with 
obesity (Adolphe et al., 2014). Weight-loss resulted in improved pancreatic b-cell function 
and insulin sensitivity (Adolphe et al., 2014). 
3.1.3 Systemic arterial hypertension 
Further more, the mechanisms of obesity that lead to renal injury are not restricted to the 
metabolism change of esterified fatty acids or to the physical compression of the kidneys. In 
humans one of the main consequences of overweight is the increase of blood pressure 
(WHO, 2000; Hall, Brands & Henegar, 1999). Between 65% and 78% of cases of 
hypertension are attributed to obesity (Mathieu, Poirier, Pibarot, Lemieux & Després, 2009). 
Clinical trials have demonstrated that weight loss in obese individuals, with or without 
hypertension, leads to a significant decrease in blood pressure (Hall, Crook, Jones, 
Wofford, Dubbert, 2002; Neter, Stam, Kok, Grobbee & Geleijnse, 2003). The increase in 
blood pressure (BP) is also associated with obesity in dogs, both in the domestic population 
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and in experimental models (Rocchini, Moorehead, DeRemer & Bondie, 1989; Bodey & 
Michell 1996; Montoya et al., 2006).  
The mechanisms by which obesity induces hypertension are not fully understood. There are 
several different factors that contribute to its development. Changes in renal function 
leading to changes in pressure natriuresis and sodium retention appear to play an important 
role in all forms of hypertension, associated or not with obesity (Hall, Kuo & Silva, 2003; 
Hall, et al., 1993). Several mechanisms seem to contribute to this phenomenon, such as 
physical compression of the kidneys (already mentioned in 3.1.1 Physical compression of 
the kidneys ), the increase of the activity of the SNS, increase of leptin and the increase of 
the RAAS activity. The latter three mechanisms will be discussed next.  
3.1.3.1 Sympathetic nervous system: 
Some clinical trials in humans suggest that obese and hypertensive individuals have higher 
activity of the SNS compared to lean individuals (Jones, Davy, Alexander & Seals, 1997; 
Grassi et al., 1995).  
The normal renal effect of the increased of sympathetic activity are: 1) the increased tubular 
reabsorption of sodium that results in sodium retention; 2) increased glomerular filtration 
rate and renal blood flow due to vasoconstriction and increased renal vascular resistance; 
3) increased renin secretion that leads to increases production of AngII (Rahmouni, Correia, 
Haynes & Mark, 2005). In humans pharmacologic blockade of adrenergic activity results in 
a reduction of sodium retention and a higher reduction of blood pressure in obese 
compared to lean individuals (Wofford, Anderson, Brown, 2001). Furthermore, studies with 
a high-fat diet in experimental dogs revealed that the denervation of the kidney resulted in a 
marked reduction of sodium retention and the development of hypertension (Kassab et al., 
1995). These observations suggest that the chronic sympathetic activation induced by 
obesity, especially the renal sympathetic nerves, is the main contributor to the development 
and maintenance of obesity hypertension (Hall et al., 2014; Silva, Bentes, Daher & Matos, 
2017). The proposed mechanisms that may be behind the increased activation of the SNS 
in obesity are hyperleptinemia, hyperinsulinemia, the increase in angiotensin II, and the 
physical compression of the kidneys due to visceral fat (already mentioned in 3.1.1 Physical 
compression of the kidneys ) (Hall et al., 2014; Silva et al., 2017).  
3.1.3.2 Leptin 
In humans, studies suggest that leptin is an essential element to regulate the activity of 
SNS and may have a role in hypertension in obesity. An experimental study with mice 
lacking the ability to synthesize leptin due to a nonsense mutation in the leptin gene (ob/ob 
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mice) and the db / db mice with nonfunctional leptin receptors, both develop severe obesity 
(Ziyadeh et al., 2000).  However, only the db / db mice had histological renal lesions, 
suggesting the possible involvement of leptin in ORG secondary to obesity, even though, 
they did not become hypertensive (Ziyadeh et al., 2000). A similar finding was reported in 
humans with deficiency of leptin by gene mutations. Although these individuals have a high 
risk to develop morbid obesity and many of the elements that make up the metabolic 
syndrome, the SNS activity remained controlled and also the blood pressure was normal 
(Ozata, Ozdemir, Licinio, 1999). Other experimental studies have shown that intra-
cerebroventricular or intravenous infusions of leptin to equalize the blood concentrations to 
ones in obesity had resulted in high renal sympathetic nervous activity and consequently 
raised the arterial pressure (Hall et al., 2002; Hall, Silva & Carmo, 2010).  
This increased arterial pressure seems to be mediated by SNS because the blocking of 
alpha- and beta-adrenergic receptors in a stage of high chronic leptin levels in obesity can 
abolish the rise in blood pressure (Hall et al., 2002; Hall et al., 2010). The mechanism by 
which leptin leads to increased SNS activity seems to involve the activation of the 
hypothalamic pathway of the pro-opiomelanocortin pathway (POMC) (Hall et al., 2014). The 
POMC is a precursor polypeptide that is inside of hypothalamus in the arcuate nucleus and 
they express in the paraventricular nucleus and lateral hypothalamus, releasing 
melanocyte-stimulating hormone, which then acts as an agonist for melanocortin 3 (MC3R) 
and 4 receptors (MC4R) (Coll, A.P., 2007). These neurons, in turn, send information to the 
nucleus of the solitary tract in the brainstem to alter appetite, SNS activity, and arterial 
pressure (Coll, A.P., (2007). The pharmacological blockade of the MC3R receptors in the 
SNS and especially MC4R, appears to abolish the acute effects of this leptin effect on the 
activation of renal SNS in mice, as well as the effects on the chronic increase of blood 
pressure (Haynes, Morgan, Djalali, Sivitz & Mark, 1999; da Silva, Kuo & Hall, 2004). Also in 
mice lacking leptin receptors in POMC neurons similar effects were observed (do Carmo, 
da Silva, Cai, Dubinion, Hall, 2011). Humans with POMC or MC4R mutations show early-
onset morbid obesity, as well as many other obesity comorbidities such as insulin 
resistence, hyperlipidemia or hyperinsulinemia but do not have increase of SNS activity or 
hypertension (Tallam, da Silva & Hall, 2006; Greenfield, 2011). Thus, it is possible that the 
POMC-MC4R system constitutes one of the main pathways between leptin, the activation 
of the SNS and the development of hypertension. Beside this mechanism leptin has the 
ability to increase natriuresis in response to a decrease of Na transport in the tubules. 
Several studies have demonstrated that acute leptin infusion stimulates the release of nitric 
oxide (NO) in endothelial cells and blood vessels, with NO being shown to decrease Na 
reabsorption in the tubules by decreasing Na, K, -ATPase (Briffa, McAinch, Poronnik, 
Hryciw, 2013). Therefore, acute leptin exposure in the kidney may increase NO expression 
in an attempt to regulate obesity-associated hypertension. However, chronic leptin 
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exposure further compounds hypertension in the obese by increasing renal sympathetic 
activity (Briffa et al., 2013). Chronic hyperleptinemia has been shown to increase the 
activity of Na, K, -ATPase, causing Na retention by either increased renal SNS activity 
and/or decreased NO production (Beltowski, Jamroz-Wisniewska, Borkowska, Wójcicka, 
2004). Bełtowski et al. identified that hyperleptinemia causes NO deficiency primarily due to 
increased renal oxidative stress, which inhibits the protective role of NO in increasing Na 
excretion (Beltowski, Wójcicka, Marciniak, Jamroz, 2004). 
3.1.3.3 Renin–angiotensin–aldosterone system  
The RAAS is a neuro-endocrine axis closely related to both blood pressure levels and 
normal kidney function (Verlander, 2014). Numerous studies to date have demonstrated 
that the RAAS is abnormally activated in obesity and may contribute to the increase of 
blood pressure in this context (Hall et al., 2002; Hall et al., 1997; Tallam et al., 2006). 
Experimental studies in obese dogs have demonstrated that the use of inhibitors of the 
enzyme conversion of angiotensin, as well as angiotensin receptor blockers, could prevent 
the appearance of arterial hypertension (Robles et al., 1993; Hall, Shek & Brand, 1997). In 
addition, arterial hypertension in obese individuals appears to be particularly sensitive to 
agents that block RAAS activity compared to non-obese hypertensives, suggesting that this 
system may have an increased importance in the hemodynamic effects associated with 
obesity (Reisin et al., 1997; Alonso-Galicia, Brands, Zappe & Hall, 1996). 
 
Renin is a proteolytic enzyme, which has as main function to cleave angiotensinogen, 
transforming it into Angiotensin I (Verlander, 2014). Renin, is synthesized, stored and 
secreted by renal juxtaglomerular cells and its plasma concentration is the factor limiting the 
rate of angiotensin II formation (Verlander, 2014). Renin secretion is stimulated by 3 
mechanisms: by the baroreceptors of the juxtaglomerular cells present in the wall of the 
afferent arteriole in response to a drop in blood pressure; by dense macula cells in 
response to a drop in ion concentration that reaches this specialized part of the nephron; by 
the β 1 adrenoreceptors of the juxtaglomerular cells when there is sympathetic stimulation 
(Verlander, 2014). Thus, the increase sodium reabsorption that occurs in the loop of Henle 
in obese individuals and the consequent decrease in the amount of this ion that reaches to 
macula densa may be one of the explanations for the increase of the plasma renin activity 
associated with obesity (Kopple, et al., 2010; Hall et al., 2004). Increase in SNS activity 
observed in obese individuals, as previously mentioned, may also contribute to an increase 




Angiotensin I is processed by the angiotensin-converting enzyme (ACE) into angiotensin II, 
which is the most active element of RAAS (Verlander, 2014). Angiotensin II stimulates 
sodium retention and aldoesterone secretion directly, factors that contribute to an increase 
in blood pressure (Hall et al.,1999). In addition, angiotensin II leads to contraction of 
efferent glomerular arterioles, which consequently leads to increased peritubular capillary 
sodium reabsorption as well as increased glomerular hydrostatic pressure (Hall, Brands & 
Henegar, 1999). The activation of RAAS, especially through angiotensin II, may contribute 
to the appearance of glomerular lesions in obese individuals through the elevation of the 
glomerular pressure caused by the increased blood pressure (Hall et al., 2014; Hall et al., 
1999). On the other hand, the increase in angiotensin II appears to be related to renal 
ischemic and secondary damage due to the vasoconstriction and the decreased renal blood 
flow (Long, Price, Herrera-Acosta & Johnson, 2004). Finally, angiotensin II stimulates the 
proliferation and hypertrophy of vascular and mesangial cells; activates renal fibroblasts, 
leading to their differentiation in myofibroblasts; stimulates the production of TGF-b; induces 
oxidative stress and stimulates the production of chemokines that may cause local 
inflammation and result in a significant impairment of renal function (Xu et al., 2017; Aroor 
et al., 2013). 
3.1.4 Low chronic inflammation state 
The exaggerated expansion of adipose tissue results in an aberrant production of pro-
inflammatory adipokines such as tumor necrosis factor-α (TNF-α), monocyte chemotactic 
protein-1 (MCP-1), interleukin-6 (IL-6), that leads to a state of low-grade inflammation 
(Trajcevski et al., 2013). In addition to the expansion of adipose tissue, there are increases 
in macrophages migration to the adipocyte region, which increase the expression of these 
inflammatory substances (Armstrong & Lusby, 2011).  
Studies have shown the correlation between elevated expressions of these pro-
inflammatory cytokines or chemokines (TNF-α, IL-6, MCP-1) in adipose tissue with renal 
inflammation (increased TNF-α, MCP-1, IL-6 and infiltrated macrophages) in rodent models 
of obesity (Stemmer, et al., 2012; Mori et al., 2014). In obese dogs increases in serum 
concentrations of inflammatory markers (increased C-reactive protein and IL-6, but not 
TNF-α) have also been found (Frank et al., 2015), with increased macrophage infiltration in 
adipocyte tissue (Weisberg et al., 2003; Lumeng et al., 2007), and some studies, but not all, 
have been found decreases in such markers and other cytokines (MCP-1, TNF-α) with 
weight loss (Tvarijonaviciute et al., 2012; German et al., 2009; Wakshlag et al., 2011). 
Among the large number of pro-inflammatory adipokines, TNF-α, that can be synthesized 
by adipocytes, macrophages, mast cells, fibroblasts and neuronal cells (Armstrong et al., 
2011), is one of the main critical mediators of adipose tissue inflammation. The infusion of 
39 
 
TNF-α in rat induced rapid changes in adipocyte gene expression, favouring pro-
inflammatory cytokine production with a reduction of adiponectin, an anti-inflammatory 
adipokine (Ruan et al., 2002). 
Beside the increased of TNF-α level, the production of MCP-1, a chemokine produced by 
adipocytes and macrophages, is usually increased too with excessive fat storage (Bremer & 
Jialal, 2013). This chemokine is recognized as one of the mediator of adipose tissue 
inflammation because of its effects on macrophage recruitment into the adipose tissue 
(Kanda et al., 2006). The deficiency of MCP-1 or its receptor was shown to induce a 
reduction of macrophage infiltration in the adipose tissue in obese experimental models 
(Kanda et al., 2006). 
In obesity these two pro-inflammatory adipokines are upregulated while anti-inflammatory 
adipokines such as adiponectin are down-regulated (Declèves & Sharma, 2015). This anti-
inflammatory adipokines, adiponectin, is one of the most abundant adipokines produced by 
the adipocytes and it is decreased in obesity (Kadowaki et al., 2006). The anti-inflammatory 
effect of adiponectin, acts by stimulating enzyme AMP-activated protein kinase (AMPK) that 
have protective effects on podocytes (Rutkowski et al., 2013). The AMPK activation is a key 
regulator of lipid storage in kidney (Declèves et al., 2015). A significant lipid accumulation in 
proximal tubular cells along with impaired brush border and podocytes, as associated with 
increased of indicators of cell damage and inflammation by the present of high nitrotyrosine 
levels suggesting tubular dysfunction. However, this effect can be blocked by adiponectin or 
AMPK activation (Sanchez et al., 2011) 
In obese individuals, as well as in dogs, the leptin is in high levels, as mention previously, 
which is responsible for upregulating TGF-β and TGF-β receptor II (Young, Morgan, Butler, 
Mark & Davisson, 2013; Nasrallah & Ziyadeh, 2013). These induce type I and type IV 
collagen fiber formation in the mesangium, promoting fibrosis, and overactivates SNS, 
which induces renal hemodynamic changes and renal damage (Young, Morgan, Butler, 
Mark & Davisson, 2013; Nasrallah & Ziyadeh, 2013). 
The chronic, low state of inflammation that accompanies the accumulation of WAT and the 
increases of inflammatory marker concentration in serum provides evidence that obesity-
induced inflammation may have an important pathogenic role in the development and 
progression of kidney injury. 
3.1.5 Structural and functional changes of kidneys due to obesity  
In the study performed by Heneger et al. (2001) structural alterations of the renal 
parenchyma (enlargement of Bowman’s space, increased glomerular cell proliferation, 
increased mesangial matrix, thicker basement membranes, and increased expression of 
glomerular transforming growth factor) were observed a few weeks after a rapid increase in 
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weight in experimental dogs. These early renal changes occurred with only modest 
hypertension, no evidence of diabetes, and only mild metabolic abnormalities (Heneger et 
al., 2001). According Hall et al., deposition of mesangial matrix, glomerular basement 
membrane thickening, and fibrotic changes in obesity, at an early stage may protect the 
kidney of glomerular capillary overstretching despite increased glomerular hydrostatic 
pressure due to renal vasodilation and elevated arterial pressures (Hall et al., 2014). 
However, long-term arterial hypertension leads to renal damage and reduced filtration 
surface area thus contributing to a positive feedback mechanism that further increases 
glomerular pressure and leads to additional renal injury and eventually progressing to CKD 
(Hall et al., 2014). This slowly developing vicious cycle may be accelerated if other 
metabolic derangements induced by obesity are present such as hyperglycemia, 
inflammation, oxidative stress, and dyslipidemia (Hall et al., 2014)..  
In Humans, glomerulosclerosis (segmental and focal) is the histological type of glomerular 
disease most often associated with obesity (Ahmed & Khalil 2007; Kasiske & Napier, 1985). 
Segmental and focal glomerulosclerosis associated with obesity is distinguished from 
idiopathic segmental and focal glomerulosclerosis because the former has lower incidence 
of nephrotic syndrome, is more benign, and has slower progression to renal failure (Ahmed 
et al., 2007). 
Clinically, in humans, obesity-associated nephropathy manifests itself with nephrotic 
proteinuria prior to the onset of azotemia, and it is independent of other renal disease-
associated conditions (Kambham, Markowitz, Valeri, Lin & D'Agati, 2001). The magnitude 
of proteinuria correlates with the severity of obesity and there is a significant correlation 
between weight loss and proteinuria reduction (Kambham et al., 2001; Griffin et al., 2008). 
In dogs, it is not clear yet. In the study with dogs with experimentally induced obesity, as 
mentioned, urine protein excretion was not determined prior to or following forced increases 
in BW (Heneger et al., 2001). A recent prospective study that evaluated the effect of weight 
loss in dogs with naturally occurring obesity showed a significant reduction in UPCR 
occurred after weight loss (Tvarijonaviciute et al., 2013). However, another study that 
evaluated the association between obesity and proteinuria did not revealed a significant 
difference in urine protein and albumin excretion between the overweight/obese dogs and 




Figure 3 - Pathophysiology of the association between obesity and kidney disease. Adapted 
from  Silva et al., 2017 
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IV. Nutritional Treatment 
In this section, the treatment of obesity will be briefly discussed as well as the combination 
of obesity with CKD, how we should face it and what are the advantages and 
disadvantages of carrying out a weight loss plan according to the stage of CKD. 
As already mentioned, obesity, without other concomitant diseases, is one of the simplest 
pathological conditions to diagnose but on the other hand, difficult to treat because besides 
choosing the right diet and designing the dietary plan, it´s necessary for the veterinarian to 
have dedication, patience and time as well as for the owners to recognize and understand 
the problem, and committing themselves to follow the plan  (Churchill & Ward, 2016; 
Murphy, 2016). The basis of the treatment for weight-loss in overweight pets is calorie-
restriction and avoiding regain of the lost weight (Michel et al., 2012; Toll et al., 2010). In 
order to develop a weight-loss program the first step is to perform a full physical exam. The 
results from the exam will help to find the conditions that may have influenced the weight 
gain (concomitant pathologies as hypothyroidism or hyperadrenocorticism), or that should 
be considered when defining the weight-loss plan (e.g., CKD), as well as the conditions that 
may influence the ability of the animal to exercise (Churchill et al., 2016; Murphy, 2016). 
Another imperative step for the success of a weight-loss plan is to establish a complete 
dietary history to understand who feeds the animal, how and when it is fed, which diet, and 
the amount of food the dog eats (Michel et al 2012; Toll et al 2010). After that, the three 
main keys components to be to take into account are alteration of behavior, the activity 
level and the diet (Debraekeleer, 2005; Case et al., 2000). To understand these three main 
keys better, first we have to approach the energy and how to restrict it as the basis of a 
weight loss plan is to increase energy expenditure in relation to energy intake (Toll et al., 
2010). 
1 ENERGY RESTRICTION 
The level of energy restriction depends mainly on the degree of weight excess, the actual 
energy intake, and the projected duration of weight loss (Diez & Nguyen, 2010, Fascetti et 
al 2012). The underlying rationale in a weight loss plan is that weight loss should be gradual 
to minimize lean tissue loss and to avoid a regain of BW at the end of the programme 
(Laflamme & Kuhlman, 1995). Determining caloric restriction in dogs can be obtained by 
several methods. One of them is by calculation based on current food intake , which 
requires an accurate diet history to allow an estimation of patient’s daily caloric intake. This 
calculation will correspond to the maintenance energy requirement (MER) for the current 
body weight. The MER is the amount of energy required to maintain an animal in a state of 
43 
 
energy balance, or in other words, the amount of energy needed to maintain an animal at 
its current weight (and body composition) (Toll et al., 2010). A reasonable starting point for 
daily calorie intake in a weight loss plan is to feed only 60-70% of that MER calculated (Toll 
et al., 2010). Unfortunately, an accurate diet history is not always easy to get because the 
owner could give an inaccurate report due to concerns of having been “feeding too much” 
or do not know the right amount they are giving. This makes it difficult to calculate the 
correct MER, and consequently cause a risk of restricting too much the energy or the 
opposite (Toll et al., 2010). Therefore, an alternative and more frequently used option is 
RER. RER correspond to the energy that the animal expends when it is lying down. It is 
often measured in animals that are not fasting, and therefore it may contain some energy 
associated with the digestion of food (Toll et al., 2010). This term of resting energy is more 
often used in pet because is difficult to have an animal totally cooperate under this 
conditions: postabsorptive state under thermoneutral conditions (i.e., no additional energy 
expenditure is required specifically to maintain body temperature) with the subject lying but 
awake and in complete muscular repose) (Toll et al., 2010). The patient’s RER should be 
calculated using an estimate of the optimal BW based on BCS (RER in Kcal = 70 x body 
weight [BW]kg^0.75), because this reflects the energy needs of metabolically active tissues 
(e.g., cardiac muscle, the central nervous system) (Toll et al., 2010; Michel et al., 2012). 
Using RER as a basis for weight loss has been shown to be effective and well tolerated 
(Wakshlag et al., 2012; Michel et al., 2012; German et al., 2011). Regardless of which way 
is used, this is just a starting point because some overweight pets may already be eating 
close to those calculated amounts, and further calorie restriction will be required to achieve 
weight loss.. This will need adjustment over time to achieve a right rate of weight loss until 
the patient reaches the correct weight, which depends on each pet and their circumstances 
(Brooks et al., 2014). Laflamme showed in 1995 that the greater the caloric restriction, the 
greater is the weight loss and more quickly. However, the same dogs with higher rate of 
weight loss were the ones with greater predisposition to regain the weight when they came 
off of the diet (Laflamme & Kuhlman, 1995). Moreover, Laflamme & Hannah in 2005 has 
shown that different rates of weight loss may provide additional benefits. In that study they 
showed that a rate of 1% of body weight loss per week could limit risk of nutrient deficiency, 
loss of lean body mass, and rebound weight gain (Laflamme & Hannah, 2005). Therefore 
AAHA Weight Management Guidelines recommend that rates of successful weight loss 
range from 0.5% to 2% of weekly body weight loss for dogs (Brooks et al., 2014) 
Finally, a diet and dosage must be chosen for the animal and the animal should be 
rechecked every two to four weeks for weight and to adjust the feeding management to 




Table 4 – Summary of a weight loss programme for healthy overweight dogs (Michel et al., 
2012) 
1º physical examination including BCS; 
2º Obtain a diet history; 
3º Weigh the patient and set the weight loss goal; 
4º Estimate the patient’s optimal BW; 
5º Estimate the patient’s current MER from the diet history or RER from the optimal BW; 
6º Set the level of caloric restriction; 
7º Choose the diet and calculate the food dosage; 
8º Recheck the patient every two to four weeks for weight. Adjust feeding management to 
target weight loss at 1% to 2% of BW/ week and address any problems or owners 
concerns.	
BCS – body consition score; BW – body weight; MER – maintenance energy requirement; RER – rest energy 
requeriment; BW – body weight 
2 DIETARY CONSIDERATIONS 
One of the first considerations of a weight lost diet is to ensure that it is well balanced. All 
nutrient requirements, such protein, essential fatty acids, vitamins and minerals must be 
present in amounts sufficient to support normal physiologic processes and retention of lean 
body tissue, even when calorie intake is insufficient to maintain body weight, otherwise the 
animal will have deficiencies (Toll et al., 2010). The goal of this diet should be to restrict 
only energy (Toll et al., 2010). To achieve this, pet food manufacturers decrease the energy 
density of foods by reducing fat and simultaneously increasing the fiber, air or moisture 
content of the food, which will be discussed below (Toll et al., 2010).  
In addition to caloric intake, it is important to consider the sources of those calories. Energy 
(calories) is derived from three macronutrients: protein, fat, and carbohydrates. A selection 
of an optimal proportion of these macronutrients should be considered when selecting a 
diet for each pet. Pets with comorbidities such as CKD, additional nutritional considerations 
are necessary. However, this consideration depends on the stage of CKD. In humans, the 
obesity paradox has been observed where renal patients with advanced CKD or end stage 
renal disease have lower mortality rates (Kovesdy, Anderson, Kalantar-Zadeh, 2007; 
Beddhu, Pappas, Ramkumar, Samore, 2003). However, these protective effects of higher 
BMI showed that is of short-term and is in contrast with the deleterious effects of longer 
term of obesity (Snyder, Foley, Gilbertson, Vonesh, Collins, 2003). Also, in dogs, higher 
BCS at the time of diagnosis was associated with improved survival (Parker, Freeman, 
2011). In this study, underweight CKD dogs with a body condition score (BCS) of 1-3/9 had 
a significantly shorter median survival time compared with moderate (BCS 4-6/9) and 
overweight dogs (BCS 7-9/9), with no difference between moderate and overweight 
(Parker, Freeman, 2011). There are several putative short-term benefits such as better 
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nutritional status typically seen in obese individuals, which provides better protein and 
energy reserves in the face of acute illness, and a higher muscle mass with enhanced 
antioxidant capacity (Beddhu, Pappas, Ramkumar, Samore, 2003). Other hypothetically 
beneficial characteristics of obesity include a more stable hemodynamic status with 
attenuation of stress responses and increase of sympathetic and renin-angiotensin activity 
by adipose tissue neutralizing the adverse effects of tumor necrosis factor alpha and 
sequestration of uremic toxins by adipose tissue (Horwich  et al., 2001; Jandacek et al., 
2005). Therefore, the implementation of a weight loss program in patients with later-stages 
of CKD (International Renal Interest Society (IRIS) stage 3-4) may be not reasonable and a 
therapeutic kidney diet would be more appropriate to control the symptoms and to minimize 
them (e.g., azotemia, uremia, proteinuria). However, prescribing a weight loss diet for a 
obese dog in earlier stages (IRIS stage 1 and 2) with mild renal azotemia (lower end of the 
range lies within reference ranges) and clinical signs usually mild or absent (e.g., 
inadequate urinary concentrating, abnormal renal palpation or renal imaging findings, 
proteinuria of renal origin, abnormal renal biopsy results) would be beneficial. Nonetheless 
the diet should meet some requirements beside the low energy density and fat restriction 
such as moderate high quality protein and, low in phosphorus, moderate to high fiber. This 
requirement will be discussed below. 
 
Protein and phosphorus: 
High quality protein diets with reduced energy density help to maintain lean body mass 
during weight loss in dogs (Hannah & Laflamme 1998; Laflamme et al., 2005). Another 
benefit of these diets is the thermic effect, as protein ingestion results in increased energy 
expenditure in contrast with equal energy consumed from fat or carbohydrate (Toll et al., 
2010, Loftus et al., 2015). Furthermore, the satiety effect of a high-protein diet is higher 
than with high-fat or carbohydrate diets (Diez et al., 2007). The quantity of protein 
recommended by Toll et al. (2010) for weight-loss is at least 25% dry matter (DM) crude 
protein to help prevent loss of lean body mass (Toll et al., 2010).  
However, when kidney disease is present, the primary concern is the kidney and a general 
consensus of opinions supports the fact that reducing protein intake improves clinical signs 
in animals with kidney disease, especially in stages 3 and 4 (Ross, 2017). The rationale 
behind the limiting of protein intake in CKD patients is that the reduction of nonessential 
proteins will result in decreased production of nitrogenous waste with consequent 
improvement of clinical signs of uremia (Polzin, Osborne, Adams, O’Brien, 1989; Forrester, 
Adams, Allen 2010). A study of Polzin et al. compared the efficiency of three diets 
(maintenance diet with 44% protein in DM and two protein restriction diets with 8.2% and 
17.2% DM) provided for 40 weeks for dogs with induced CKD (Polzin, Osborne, Stevens, 
Hayden, 1983). The animals that received the restricted diets showed a reduction in 
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mortality, reduction in BUN concentration, as well as clinical manifestations secondary to 
uremia (Polzin et al. 1983). Also dietary protein restriction (35%vs 14% DM) showed a 
decreased proteinuria in dogs with spontaneous glomerular disease (Burkholder et al., 
2004). A decreased protein intake may reduce tubular hyperfunction by reducing acid load 
and renal ammoniogenesis. In general, protein metabolism is the largest generator of H+ 
ions, and when protein intake is reduced, diet helps to maintain the acid-base balance 
(Relman, Lennon, Lemann, 1961; Forrester et al., 2010). The type of protein can also have 
an influence. Animal protein (eg, methionine and cysteine) has higher sulphur content than 
vegetal protein, which contributes to the increase of renal acid load (Forrester et al., 2010). 
The reduced of protein intake can lead to catabolism of body energy reservoirs, if there is 
insufficient energy provided (carbohydrates and fats), including protein catabolism for the 
use of amino acids in gluconeogenesis. Therefore, it is necessary to avoid protein excess, 
but without imposing deficiency (Burkholder, 2000; Forrester et al., 2010). The study by 
Brenner, Meyer and Hostetter (1982) showed that excessive consumption of protein was 
associated with glomerular hypertension and hyperfiltration in rats (Brenner, Meyer, 
Hostetter, 1982). With the reduction of protein intake, these hemodynamic changes were 
reduced and preservation of the normal glomerular structure was observed (Brenner et al., 
1982). As mentioned above, in a weight loss diet the high quantity of protein helps to 
prevent loss of lean body mass and helps in the satiety. However, for a dog with a 
combination of these two diseases  reducing in protein would be more beneficial because it 
can reduce proteinuria and signs of uremia. In humans proteinuria or albuminuria is one of 
the principal signs of renal injury secondary to obesity (Chang et al., 2013; Foster et al., 
2008; Praga et al., 2000). Also in dogs UPCR is higher in obese dogs, although they did not 
have proteinuria (Tefft et al., 2014).  
The minimum recommended by NRC allowances for DM dietary protein in foods for healthy 
adult dogs 10% and the recommended allowances are 18% (Forrester et al., 2010; 
FEDIAF, 2013). The recommendation for dogs with obesity is at least 25% by Michel, in 
Fascetti and for the kidney disease is 14%-20% according to Forrester et al., 2010 (Michel, 
2012; Forrester et al., 2010). Therefore, the recommendation for the combination of this two 
diseases is between 13 to 20% DM crude protein (Bartges and Rakitic, 2010; Michel, 
2012). However it’s important to still monitor for signs of protein deficiency.  
 
Fat:  
The fat in a weight-loss diet should be reduced due to its high energy density. The 
recommended upper limit for dietary fat for weight loss in dogs is 6-11% DM (Toll et al., 
2010, Bartges et al., 2010). However, at the same time it should cover the essential fatty 
acids and fat-soluble vitamin requirements. In particular, the omega-3 fatty acids that have 
anti-inflammatory effects in primary renal failure are of interest (Michel et al., 2012, Toll et 
47 
 
al., 2010, Loftus et al., 2015, Bartges et al., 2010). Studies in laboratory-induced renal 
disease in dogs have reported that supplementation with menhaden fish oil (rich in omega-
3 polyunsaturated fatty acids) was considered to be renoprotective compared with safflower 
oil (rich in omega- 6 polyunsaturated fatty acids) and beef tallow (rich in saturated fatty 
acids) (Brown et al., 1998). It was also described that dogs fed menhaden fish oil had 
lowered glomerular capillary pressure, reduced proteinuria, and slowed progressive decline 
in the glomerular filtration rate (Brown et al., 1998).  
 
Carbohydrates: 
In a weight-loss diet, carbohydrates can be used to lower glycemic index, to shift the 
metabolism of energy storage to energy usage and to increase satiety (Toll et al., 2010). 
There are three categories of carbohydrates based on composition: 1) simple sugars such 
as monosaccharides (e.g., glucose) and disaccharides (e.g. sucrose), 2) oligosaccharides 
(three to nine sugar units; e.g., raffinose, stachyose) and 3) polysaccharides [more than 
nine sugar units, e.g. starches (amylose, amylopectin or glycogen) hemicellulose, cellulose, 
pectins, gums]. In nutritional sense the polysaccharides are commonly known as complex 
carbohydrates. These ones are divided in starches, if they are digested by the animal 
endogenous digestive enzymes or “labeled fibers” if they are fermented by intestinal 
microbes (Gross, et al., 2010). After digestion and absorption of starches or simple sugars, 
the glycemic index increases immediately, in parallel with the increase in insulin levels 
(Diez & Nguyen, 2007). Carbohydrates that result in a low postprandial blood glucose 
response have a lower glycemic index and vice versa. Simple sugars are rich in glucose 
and have high glycemic index and consequently high insulin response (Diez & Nguyen, 
2007). 
  The glucose in excess, can be used in lipogenesis, and can be transformed into fatty 
acids, which are stored as TG (Haugen & Drevon, 2007). After a meal, lipogenesis is 
stimulated by insulin (Haugen & Drevon, 2007). The importance of a low glycemic index 
and, consequently, a decreased response of insulin in a weight loss diet with reduced 
simple carbohydrate content is to decrease the lipogenesis and favor mobilization of fats 
(Diez & Nguyen, 2007).  
The dietary fiber is one of the most important ingredients in weight loss diets, mainly the 
insoluble fiber, which besides diluting calories also increases satiation. Insoluble fiber 
increases the bulk in gastrointestinal (GI) tract and consequently increases the gastric 
distension; it decreases the absorption capacity of energy by interfering with the digestion 
and absorption of fat, protein and digestible carbohydrate (Michel et al., 2012; Toll et al., 
2010; Loftus et al., 2015). Moreover, the utilization of fermentable or soluble fiber can 
improves GI health in the case of renal patients, (Toll et al 2010; Bartges et al., 2010). 
Fermentable or soluble fiber is a source of energy for GI bacteria. In order to grow, bacteria 
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can use BUN as a source of nitrogen, which subsequently increases the fecal nitrogen 
excretion in the form of the bacterial cell mass and decreases the urinary nitrogen excretion 
(nitrogen-trap effect) (Younes et al, 1995; Younes et al, 1996). Studies in partially 
nephrectomized rats with supplementation of fermentable fiber (gum arabic) in wheat 
starch-based diet showed a decrease in BUN concentration; however, there were no 
differences in total nitrogen excretion, but a shift from urinary to fecal nitrogen excretion 
(Younes, Garleb Behr, Demignéa, Rémésya, 1998). There is one study published to 
validate this hypothesis in dogs. Eight healthy dogs were randomly assigned to one of two 
treatment groups. One was fed with low-protein diet with insoluble fibre (cellulose) and the 
other was fed with fermentable fibres containing sugar beet pulp and guar gum mix 
(Wambacq, et al., 2016). The group fed with the fermentable fiber showed increased 
fermentation-derived propionic acid and its metabolites can be used as alternative 
substrates for gluconeogenesis which spares amino acids and reduces the kidneys’/liver’s 




Another important nutrient that is very important to take into account when kidney disease 
is present is the quantity of phosphor, which should be reduced to avoid the occurrence of 
hyperphosphatemia. When kidneys lose the functional capacity, an imbalance in calcium 
and phosphorus metabolism occurs, which leads to a stimulation of the parathyroid to 
produce parathyroid hormone in an attempt to maintain calcium homeostasis, because in 
general, hypocalcemia occurs in CKD (Diez & Nguyen, 2010). This phenomenon is called 
secondary renal hyperparathyroidism manifested through demineralization of bone and 
calcium deposition in soft tissues including the renal parenchyma (Diez & Nguyen, 2010). 
Slatopolsky et al. (1971) showed that phosphorus restriction reduced GFR by up to 1/4 in 
the dogs fed a phosphorus-restricted diet (intake less than 100 mg per day / animal). 
However, the serum PTH concentrations remained virtually unchanged. Nonetheless the 
dogs that received the unrestricted diet (intake of 1200 mg of phosphorus per day / animal), 
presented an increase of serum PTH by up to 20 times (Slatopolsky et al. 1971). Also, 
Brown et al. 1991, showed that animals fed with lower amounts of phosphorus in the diet 
had lower plasma concentrations of phosphate and creatinine (Brown, Crowell, Barsanti, 
White, Finco, 1991). The veterinary therapeutic renal foods are formulated with limited 
dietary phosphorus besides the protein restriction and have showed beneficial effects on 
dogs with naturally occurring CKD. One study was performed by Jacob et al., 2002, that 
showed the used of a kidney diet (14%DM protein, 0.28% DM phosphorus and 1.6% DM 
omega-3 fatty acids) in dogs with spontaneous IRIS stage 2 or greater CKD had a delay on 
the median time to uremic crisis (615 days) compared to dog on a maintenance diet (25% 
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DM protein, 1% DM phosphorus and 0.22% DM omega-3 fatty acids) that had higher 
median times to uremic crisis (252 days) (Jacob et al., 2002). At the end of this study, only 
33% of dogs in the therapeutic kidney diet group died of a renal-related cause compared 
with 65% of dogs in the maintenance group (Jacob et al., 2002).  
In a weight loss diet the concentration of phosphorus is not taken into account. However, 
when a weight loss program is prescribed to an obese patient with kidney dysfunction, a 
diet with low phosphorus content should be chosen. The recommended phosphorus levels 
for foods used to manage CKD are 0.2 to 0.5% DM for dogs to achieve beneficial effects 
according to Forrester et al., 2010 (Forrester et al., 2010). 
 
Sodium: 
Sodium is also one mineral that should be in low to moderate quantities in patients with 
CKD to help in the reduction of blood pressure, although there is no evidence yet in studies 
with dogs (Bartges et al., 2010). The rationale is based on the reduced ability of the 
remaining nephrons to excrete sodium, and the concern that whole body sodium 
accumulation would contribute to the development of hypertension (Toll et al., 2010).   
 
Antioxidants: 
Because oxidative stress in overweight patients is increased, which contributes to diseases 
associated with obesity, supplemental antioxidants are recommended for weight-loss foods 
as well as in CKD, due the benefits that they bring (Toll et al., 2010). Humans with chronic 
kidney disease have been shown to have oxidative stress with lower concentrations of 
vitamin E and vitamin C (Cochrane & Ricardo 2003; Locatelli et al. 2003). Exogenous 
antioxidants such as vitamin E, vitamin C, carotenoids and flavanols promote a more 
favorable redox state in the body in order to minimize oxidative damage (Brown, 2008). 
Together, antioxidant systems work collectively to eliminate and neutralize free radicals and 
minimize oxidative stress (Brown, 2008). Yu and Paetau-Robinson (2006) showed that 
supplementation with vitamin E, β-carotene, and vitamin C in cats with naturally occurring 
stage II chronic kidney disease reduced markers of DNA damage (Yu & Paetau-Robinson, 
2006). In dogs with surgically induced renal mass reduction, Brown (2008) reported that 
supplementation with vitamin E, carotenoids, and lutein, slowed the rate of reduction of the 
glomerular filtration rate, compared to dogs that did not receive antioxidant supplementation 
(Brown, 2008).   
 
Supplements: 
Beside the nutrients that are important for the weight loss diet and CKD, there are 
supplements that can be add to the diet to help in weight-loss. Carnitine, for example, 
promotes shuttling of cytosolic long-chain fatty acids across the mitochondrial membrane to 
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promote their β-oxidation within the mitochondrial matrix, which may increase the rate of 
weight loss while promoting retention of lean body mass in companion animals during 
caloric restriction; nonetheless, the studies show inconsistent effects (Loftus et al., 2015; 
Toll et al., 2010). Another supplement is green tea extract. In dogs with obesity-induced 
insulin resistance, green tea extract (80 mg/kg) resulted in enhanced insulin sensitivity and 
decreased triglyceride levels after 12 weeks of supplementation (Serisier et al., 2008b).  
 
Water: 
Other important factor in renal patients is water since they are often dehydrated (Michel et 
al., 2012; Toll et al., 2010; Bartges et al., 2010). Canned diets have more water, and 
consequently they can increase the water consumed and improve the fluid balance in renal 
patients; Further the energy is more diluted per volume, which can help to increase the 
satiety (Bartges et al., 2010).  
 
Feeding habits:  
For the weight loss programme to be successful, it is very important to have total 
compliance and dedication of the owner and adjust the programme to the lifestyle of the 
patient’s household as much as possible. It is suggested that: the owner starts to quantify 
and monitor the food intake with the right amount of specific diet calculated; all kinds of 
human food have to be eliminated; if the owner want to give treats, the amount per day is 
fixed and the calories from the treats have to be subtracted from the established daily diet; 
the animal should not be present in the kitchen during the cooking and at the time of the 
owners' meals (Fascetti et al 2012). To take advantage from the obligatory energy cost of 
digesting and absorptions food, the animal should be fed multiple small meals during the 
day, at least two portions, fed 8-12 hours apart, than a single large meal per day (Fascetti 
et al 2012). Also when CKD is present multiple small meals can help to avoid high post-
prandial BUN concentrations, which decrease the probability of nausea and the signs of 
uremia (Forrester et al., 2010). Obese patients with later stage of CKD and presence of 
uremia and other signs of systemic disease may be partially or completely anorectic and 
require alternate feeding methods such feeding tube (Forrester et al., 2010). However, 
encouraging acceptance of the diet should be taken into account such as the palatability 
like warming, adding water or flavoring agents to dry food, such as tuna juice, clam juice, 
chicken broth, low-sodium soups, garlic, brewer’s yeast or sweeteners such as honey or 
syrup (Forrester et al., 2010). 
 
Exercise:  
While energy restriction is the most important part of a weight reduction plan for an obese 
dog, increasing energy expenditure is another way to achieve a negative energy balance. 
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Therefore, to increase energy expenditure it is imperative to increase physical activity. 
However, this is recommended in dog without any other comorbidity. Nonetheless, in 
humans studies showed that regular exercise in patients with CKD increases muscle 
strength, prevents muscle wasting and also improves the cardiovascular health and the 
nutritional parameters, as well as reduces chronic inflammation (Heiwe, Jacobson, 2011).  
In a weight loss programme, the introduction of physical activity should be gradual and at 
tolerable intensities, due to the intolerance to exertion and respiratory distress experienced 
by obese animals (Fascetti et al 2012; Hand et al 2010). No optimal levels of activity have 
been established for dogs that eat low-energy foods. However, the recommendation from 
AAHA is a 5 min walk three times/day for an obese dog with no orthopedic restrictions, and 
increase gradually until either the client’s or pet’s limit is reached or once a total of 30–45 
min of walking/day has been achieved (Brooks et al., 2014). 
Beside the increase of energy expenditure, exercise helps to maintain lean mass. In 
humans, the practice of exercise during a weight loss attenuates the muscle protein 
catabolism, shows higher levels of retention of lean mass, improves in insulin sensitivity, 
and increases strength and function (Votruba, Horvitz, Schoeller, 2000; Curione, Lourenco, 
2005). These positive effects of exercise during weight loss in dogs have been studied too. 
The dual energy x-ray absorptiometry (DEXA) demonstrated that lean mass in exercised 
dogs (exercised 3 times/week at the university hospital, and increase daily activity level at 
home) during a dietary weight loss plan was maintained when compared with a control 
group that maintained the normal daily exercise routines during the study period (Vitger, 
Stallknecht, Nielsen, Bjornvad, 2016). Another study showed that exercised dogs have 
higher expression of genes involved in glucose utilization in muscles and also has higher 
preservation of lean mass, which may reflect a positive influence on insulin signaling during 





Figure 4 - Algorithm – Nutritional management of concurrent canine obesity (Bartoes & 




Patient with BCS >5 out of 9 
Calculate RER using an 
estimate of the optimal BW 
based on BCS. 
(RER(Kcal)=70x[BW]kg^0.75 
1. Complete diet history 
2. Discuss with the owner the health impact of overweightness /obesity, educate 
the owners and show the benefits of doing a weight loss programme. 
 
Does the pet have any co-morbidities? (e.g., CKD) 
Consider consultation with a board-certified 
veterinary nutritionist  
Weight loss appointment 
Is an accurate and complete diet 
history available? 
Obtain MER based on the 
food in take and feed only 
60-70% of MER. 
Create weight loss plan: 
- Select food and treat  
- calculate the food dosage 
- rate of weight loss (0,5-2%/per week) 
- Recheck the patient every two to four weeks 
for weight  
Weigh-in: Patient losing weight at desired rate? 
 
- If not at goal BCS, continue 
with the plan until the goal. 
- If at goal BCS, stop and feed 
an amount that maintains goal 
 
Losing weigh too fast: 
- Check for underlying disease(s). 
- If healthy, increase volume fed (10-20%). 
Losing weight too slowly or gaining: 
- Check for underlying disease(s) 
- if healthy, decrease volume fed (10-20%) 
Feed weight loss Diet that is CKD 
(stage 1 and 2) appropriate: 
- low energy density 
- protein: moderate, high 
quality 
- phosphorus and sodium 
restriction 
- fat restriction 









PART III – STUDY OF THE INFLUENCE OF OVERWEIGHT ON ROUTINE 
PARAMETERS OF RENAL FUNCTION IN DOGS 
1 MATERIALS AND METHODS 
This dissertation is based on part of a PhD study performed by the Animal Nutrition Lab in 
the Department of Nutrition, Genetics and Ethology, Ghent University. The study behind 
this dissertation consists of a research with the duration of one and a half years for the 
purpose of investigating the effects of obesity and overweight on renal function. The study 
involves a weight gain phase and a weight-loss phase in which routine as well as 
specialized or novel markers of kidney function were evaluated. Examples are serum 
creatinine, urea, UPCR, GFR assessed using iohexol, blood pressure, and novel urinary 
biomarkers retinol-binding protein, immunoglobulin G, etc. Furthermore, ultrasound was 
also performed, using contrast with microbubbles to provide information on renal perfusion 
of each kidney. The body composition was also analysed every 3 months through the 
deuterium oxide dilution method to accurately determine the amount of fat in each animal. 
The statistical analysis of this dissertation will focus only on the first 6 months of the study, 
and will only analyse whether weight gain in healthy adult dogs has an effect on blood urea, 
creatinine, urine specific weight and UPCR related to the renal function of dogs. 
1.1 Study design  
The study was designed to determine the relationship between obesity and kidney disease 
in dogs during a period of 6 months in 16 beagles.  
This study was approved by the Ethical Committee of the Faculty of Veterinary Medicine, 
Ghent University, Belgium. 
1.2 Animals and diet 
Sixteen healthy adult Beagle dogs averaging 5,5 years (range 8.3 to 2.5) were included in 
the study. Six dogs were intact females and two others were neutered females; four were 
intact males and four neutered males. At the start of the study, all dogs had 4 weeks of 
adaptation to the diet and general blood parameters (blood count and biochemistry to 
analyze kidney and liver function, total proteins and thyroid hormone function) were 
performed to verify the health condition of animals. Urinalysis and analysis of urinary 
sediment and urine culture were also performed to exclude infectious or inflammatory 
processes and to understand the origin of proteinuria. All the dogs had an initial median of 
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BCS 4 out of 9 (13 dogs with BCS of 4 and 3 dogs with BCS of 5) and they received the 
same high energetic diet for 6 months. The diet was a commercial maintenance diet, high in 
fat and protein and met adequate nutrient requirements of the National research council 
(NRC) recommendations (National Research Council, 2006). The analysed nutrient 
composition of the diet is shown in Table 6. The dogs were fed at an estimated 
maintenance energy requirement for laboratory beagles, which was adapted to the BW 
evolution of each individual dog (Table 5). 
 
  Table 5 – Calculation of the daily energy requirement’s in the two groups   
Treatment group Control group 
(kJ) MER = RER x 1.3 x Activity level (kJ) MER = RER x Activity level  
(kJ) RER= 293 x BW^0.75 (kJ) RER= 293 x BW^0.75 
Activity level = manually assigned to 
each dog 
Activity level = manually assigned 
to each dog 
 DER (daily energy requirement); RER (rest energy requirement); BW (body weight); MER 
(maintenance energy requirement); Kj (kilojoule) 
 
Table 6 – Analysed nutrient composition (%) of the experimental diet 
Diet Composition 
Dry matter 91 
Crude protein 35 
Crude fat 17 
Crude fiber 5 
Nitrogen free extract 25 
Metabolizable energy 1498 KJ 
 Kj (kilojoule) 
 
BCS and BW were measured weekly and the renal function was measured every 12 weeks. 
The body condition was determined with a 9-point Body condition scoring system 
(Laflamme, 1997). The 16 dogs were carefull divided into two groups in order to have equal 
amount of male and females and similar ages. One of the groups was define as the Control 
group (C) (n = 8) and the other was the group of weight gain, or treatment group (T) (n = 8. 
The C group had an average initial weight of 11.6 kg. The T group had an average initial 
weight of 11.2 kg. During the test period, the C group received MER while the T group 
received 1.3 times more of the RER to gradually increase their weight approximately 0.7% 
of BW per week to reach a state of obesity or overweight. The amount of feed given was 
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adapted to maintain the animals’ ideal BW for the control group. They were fed once a day 
in the morning.  
All the dogs were kept in compatible pairs in cages, 8 of them in 4.30 x 0.87 m 
indoor/outdoor cages, and the other 8 in 3 x 0.87 m indoor/outdoor cages. The kennels 
were heated during the winter and controlled daily. Light was provided between 7am and 
7pm, and during the night the dogs stayed inside. All dogs had free access to water. After 
all the food was finished, the bowl was removed. In case of leftovers the amount was 
measure and recorded. All dogs were allowed to walk freely once a week for the same 
amount of time on the 80m2 or 130 m2 outdoor free areas, except on sample collection 
weeks, when the free walk was in the 144m2 indoor playing area.  
1.3 Measurements  
On week 1 of the experiment, and on weeks 12 and 24 after the start, blood and urine 
samples were taken. For these purposes, all the dogs were deprived of food for at least 12 
hours 
1.3.1 Sampling procedure 
1.3.1.1 Blood sample 
On weeks 1, 12 and 24, an overnight fasting pre-prandial blood sample (8 mL) was taken 
from the jugular vein into a Blood Collection Tube with Serum Clot Activator for urea and 
creatinine. Serum was obtained by centrifugation at 2000 x g, 5 min, and 21ºC. Serum urea 
and creatinine analysis were performed on the automated clinical chemistry analyser. 
1.3.1.2 Cystocentesis 
On weeks 1, 13, 25, a sterile urine sample was taken by ultrasound-guided cystocentesis. 
The urine was collected into a falcon tube for the kidney markers (UPCR and specify 
gravity). Urine specific gravity was measured by a hand refractometer and the UPCR was 
calculated using the formula: UPCR = protein (mg/dl)/creatinine (mg/dl), after processing 
the analysis.  
56 
 
1.4 Statistical Analysis 
The data was obtained over time, so the type of statistical analysis chosen was a time 
analysis or a longitudinal analysis of the data, to search for differences in the evolution of 
the parameters over time. Data was assumed to be normally distributed and was not 
checked for the assumptions that parametric tests require. All statistical analyses were 
conducted using the statistical software programme R studio (version 3.2.5, 14/4/2016), 
namely packages gplots, lattice and ggplot2, to build up the graphs and package name, 
using the gls function for the statistical model with treatment as a fixed factor and the 
interaction of time and treatment to look for differences between treatments over time with 
dog as a random effect. 
2 RESULTS 
2.1 Body weight during the experiment  
At the start, all dogs had an ideal BCS of 4-5 out of 9 points. Throughout the study the 
control group remained stable (BCS of 4-5 out of 9 points), while the treatment group 
increased to a BCS of 6-7 (half of the group had BCS of 7). One dog in the treatment group, 
however, maintained a BCS of 5 (table 7). The body weight of the control group remained 
stable during the six months, having just physiologic oscillations, while the weight of the 
treatment group show a significant increase (p = 0,0001), which corresponded to a gain of 
0.328 ± 0.055 kg per month than the control. The total percentage that the treatment group 
increased in weight at the end of the trial was 21.5% compared with the initial weight with a 
BCS of 5. This increase of 21.5% fits on a BCS of 7 according to tablet on FEDIAF (Table 
3) means the dog become overweight (BCS 7=+20-30%).  (Table 7 and Figure 5).  
  
Table 7 - Median and range of the body condition scores and average ± standard deviation 
of weight during the experimental period (week 1, 12, 24) 
 week 1 week 12 week 24 
 Control Treatment Control Treatment Control Treatment 














Body condition score median (BCS); Average body weight;  
* time x treatment interaction (p=0.0001) ** 
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Below figure 5 shows that data variation across groups was very similar at each time point 
when live weight was measured.  
 
Figure 5 - Overview of the distribution dog weight (kg) results throughout the experimental 
period (measured at 1, 12 and 24 weeks), for all dietary treatments (each point represent a 
dog) 
 
Figure 6 - Average weight (kg) for each dietary group, throughout the experimental period 
(measured at 1, 12 and 24 weeks) 
   
 
Although figure 6 shows an increase in BW in the treatment group over time, however these 
results did not show a significant effect of time (p=0.136) on weight. The overall live weight 
at the beginning, meaning the average weight, which the two groups were equal in the trial, 
was 11.6 kg. It is also observed that there was no overall effect of treatment (p=0.770). The 
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2.2 Laboratory evaluation of renal function  
To analyze the renal function of the animals, serum urea and creatinine, the UPCR and 
urine density were examined at week 1, 12 and 24. The below table 8 shows the results 
obtained in the renal markers chosen. 
 
Table 8 – Average ± standard deviation results of renal markers weight during the 
experimental period (week 1, 12, 24) 
 





































































Urine protein/creatinine ratio (UPCR); Time effect Blood urea (p=0.062); Control (C); Treatment (T)  
 * trend time effect (0.05 < p < 0.1) 
2.3 Blood urea 
Figure 7 shows that blood urea, which were within the normal reference range (6-57mg/dl), 
did not differ between control dogs and treatment dogs. However, when plotting the 
average dog blood urea (mg/dl) over time for each group (figure 8) a linear decrease in 
blood urea over time for control dogs can be seen, whereas obese dogs show a higher 
blood urea concentration at 12 week compared to both 1 and 24 week. Statistical analysis 
shows a trend (p=0.062) for an overall effect of time on blood urea concentrations for all 
dogs (treatment and control dogs) (i.e., blood urea concentrations showed changes over 
time). On the other hand, the overall effect of treatment was not significant (p=0., 675). 
Furthermore, there were no significant differences between the groups over time (p=0.707). 
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Figure 7 - Overview of the distribution of dog blood urea (mg/dl) results throughout the 
experimental period (measured at 1, 12 and 24 weeks), for all dietary treatments (each 
point represents a dog. 
 
 
Figure 8 - Average dog blood urea (mg/dl) for each dietary treatment, throughout the 
experimental period (measured at 1, 12 and 24 weeks) 
 
2.4 Blood creatinine 
Figure 9 and 10 show that for the first 12 weeks, no differences in blood creatinine are to be 
noticed whereas at week 24, the obese dogs seem to have lower blood creatinine 
concentrations than control dogs. However, similar to blood urea, serum creatinine 
concentrations did not differ significantly between control dogs and obese dogs. The 
longitudinal model shows no overall effect of time (p=0.529) or of treatment (p=0.927) in 
serum creatinine concentrations. Further, over time, the changes in the concentrations of 
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every dog had results below of 1.4 and according to IRIS is in the normal physiologic range 
(0.3-1.3 mg/dl). 
Figure 9 - Overview of the distribution dog blood creatinine (mg/dl) results throughout the 
experimental period (measured at 1, 12 and 24 weeks), for all dietary treatments (each 
point represents a dog) 
 
Figure 10 - Average dog blood creatinine (mg/dl) for each dietary treatment, throughout the 
experimental period (measured at 1, 12 and 24 weeks) 
 
2.5 UPCR  
For this parameter, some data were missing during the trial, which it was impossible to build 
the figure by R studio. On the first urine collection at week 1 for two dogs of the treatment 
groups, there was a problem with the results at the lab. On the day of the last urine 
collection, at week 24, one dog of the control group was suffering from hyposphagma, 
which prevented the collection of urine.  
Figure 11 shows that during the 24 weeks, 14 out of 16 dogs in both groups, had a UPCR 
above of 0.2, which means that they were non-proteinuric according to IRIS (UPCR <0.5). 
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had a stable value that could be categorized as borderline proteinuric (UPCR 0.2-0.5) 
during the 24 weeks, while the other increased to values higher than 0.5, which 
corresponds with proteinuria. In the treatment group also one dog had results outside of the 
normal range of <0.2, having increased its values through the experimental period and 
became proteinuric (>0.5).  
From the statistical output, there was no overall effect of time (p=0.223) or of treatment 
(p=0.891) in urine protein/creatinine ratio. Further, over time, the changes in the 
concentrations of blood creatinine for each group were not significantly different (p=0.978).  
 
Figure 11 - Overview of the distribution dog urine UPCR throughout the experimental period 
(measured at 1, 12 and 24 weeks), for all dietary treatments (each point represents a dog) 
 
2.6 Urine specific gravity  
Similarly to what happened with the UPCR, there was one data point missing and R studio 
did not build the figure. Treatment dogs seem to show an increased urine density at 12 
weeks compared to at 1 and 24 weeks. However, in figure 12 urine density did not seem to 
differ between control and treatment dogs over time, like with the other parameters. The 
results were in the physiologic range (1.015 to 1.045) according IRIS except for two dogs 
from the control and two from the treament that showed a high concentrated urine with 
values between 1.045-1.050. However from the statistical output, there was no overall 
effect of time (p=0.721) or of treatment (p=0.806) in UPCR. Further, over time, the changes 
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Figure 12 - Overview of dog urine specific weight throughout the experimental period 
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3 DISCUSSION AND CONCLUSION 
 
 
Previous studies in humans have provided compelling evidence for close associations 
among obesity and renal dysfunction, with presence of proteinuria or albuminuria, caused 
mainly by glomerular hyperfiltration, or renal venous hypertension (Chang et al., 2013; 
Foster et al., 2008; Praga et al., 2000). These symptoms are exacerbated over time and 
with the increase of abdominal fat, leads to a loss of GFR  (Foster et al., 2008) and renal 
injuries in the glomerular region (Kambham et al., 2001) even when the common effects 
associated with obesity are absent. The weight loss tends to improve the renal function 
(Morales et al., 2003). In dogs, as study has already showed an increase the GFR and 
higher renal plasma flow as well renal injury related with the increase of weight (Henegar et 
al, 2001). Studies of weight loss in obese dogs showed that there is an improvement of 
renal function with a reduction in proteinuria (UPCR), increased urine specific gravity and 
decreased serum creatinine (Tvarijonaviciute et al., 2013).  
The current study has investigated the possible association of weight gain on the renal 
function using common blood and urine tests used in clinical practice. Healthy kidneys 
remove wastes and excess fluid from the blood. Therefore, analyzing blood and urine 
allows the clinician to assess the health of the kidney and whether the kidneys are leaking 
abnormal amounts of protein. The traditional markers of renal function in current clinical use 
are serum urea, serum creatinine, UPCR and specific gravity. These were assessed in this 
study during the 24 weeks that the treatment dogs gained weight. Although the dogs in the 
treatment group gained 21.5% of weigh, the renal markers did not differ significantly 
between the two groups over the time This suggests that the degree of overweight 
achieved in the study might not have been enough to cause renal dysfunction based on 
routine kidney markers. In contrast, the dogs in study from Henegar et al. (2001) that 
showed altered renal function had a 50% increase in weight over their initial weight in 24 
weeks.  
In this study as mention the dogs increased 21.5% weight over their initial weight which 
means a total average increase of 2.41 kg at the final of the study. The BW increased 
progressively over the 24 weeks in the treatment group, as expected. However one of the 
dogs in the treatment group did not gain weight, since it refused to eat the daily portion 
provided, thereby maintaining constant BW and BCS (5 out of 9) all over the 24 weeks. 
Therefore the average of 0.328 kg (+/- 0.050 kg) gained per month in the treatment group 
could be underestimate because it takes into account the animal that did not gain weight. 
This 21.5% of weight gained corresponds to a BCS of 7 out of 9, which means the dogs 
only achieved only an overweight status. Therefore, the obese stage was not achieved in 
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the treatment group, which means that the weight gained may have been insufficient to 
cause changes the renal markers. It should also be taken into account that this 21.5% of 
weight gain may not correspond only to gain in fat mass. Therefore, it would have been 
useful to have deuterium oxide dilution data to distinguish between fat and lean body mass 
and give a more objective value of the weight gained. 
Studies in humans revealed that obesity has a negative impact on the renal system, 
regardless of the presence or absence of diabetes, one of the major causes of CKD (WHO, 
2017; Kovesdy et al., 2017). The first sign of renal injury secondary to obesity is the 
increase of proteinuria or albuminuria, caused mainly by glomerular hyperfiltration, renal 
venous hypertension or glomerular hypertrophy which occurs in response to increased 
metabolic demand (Griffin et al., 2008). Long term or severity of obesity can lead to the 
development of glomerulosclerosis and later in CKD (Griffin et al., 2008).   
In companion dogs, it is less clear as to whether there is an association between adiposity 
and renal functional. However, one study with experimentally-induced obesity in dogs 
showed altered renal function (glomerular hyperfiltration with an associated increase of 
GFR) and histologic changes such as expansion of Bowman's capsule, cell proliferation in 
the glomeruli, thickening of glomerular and tubular basement membranes, and increased 
mesangial matrix (Henegar et al., 2001). In that study the method used to assess renal 
function was GFR measured using iothalamate. GFR is the gold standard according to IRIS 
to evaluate the renal function. However, is a not practical method in the clinical routine 
because it requires several blood collections (Heiene et al., 2015). There is currently no 
published study that assesses the renal function during weight gain in dogs and that why is 
important to evaluate renal function with routine markers in dogs that gain weight. 
Nonetheless, there is a study in obese dogs where renal function was evaluated during a 
weight loss program with routine renal markers, which showed that urea and urine specific 
gravity (USG) were both greater after weight loss than before loss, whilst UPCR and 
creatinine were less after weight loss (Tvarijonaviciute et al., 2013). Another study in 
healthy dogs showed numerically higher UPCR with higher BCS (median UPCR 0.13 and 
0.09 for the BCS of 8 and 9, respectively compared with UPCR 0.03 for BCS of 6 and 7 and 
UPCR 0.02 for BCS of 5) (Tefft et al., 2014). Nonetheless all values were within laboratory 
reference intervals (Tefft et al., 2014).  
In the current study, serum urea and creatinine was not statistically significant between the 
two groups over time (p>0.05). Serum urea increased numerically whilst serum creatinine 
decreased in the treatment group after 12 weeks of weight gain, while the control group had 
a slight decrease in the two parameters. Yamka et al. performed a study to determine which 
biomarkers differ between lean and overweight dogs and to show the effects of weight loss 
on these biomarkers (Yamka, Friesen Frantz, 2006). Their results show that overweight 
dogs had lower level of creatinine and urea than the lean dogs, and after a weight loss diet 
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with hight protein for 90 days, urea had a statistically significant increase (Yamka, et al., 
2006). However, not in all previous studies found the same effect (Diez et al., 2004). Diez 
performed a study of weight lost with two different diets: a high protein diet and a high fiber 
diet (Diez et al., 2004). The results showed that after the weight loss the urea decreased in 
the two groups with no effect of diet (Diez et al., 2004). Also, this study showed that the 
group on the high protein diet had higher values of urea during the whole study than the 
other group with high fiber diet and this was associated with the amount of protein (Diez et 
al., 2004). This could be the reason for the observed results in our study. The amount of 
given food to the two groups was different. The treatment group received a higher amount, 
which corresponded to a higher amount of protein. However, is not possible to state this 
change was due to the switch to a high protein diet because serum urea concentrations 
were not collected from the previous diet. Furthermore, the study did not include a control 
diet with low protein content in order assess diet effect. Nonetheless the treatment group 
received 1.3 times RER, which means the treatment group received 1.3 times more of 
protein during the experimental period. 
Also, other clinical conditions can increase the blood urea such as starvation, infection or 
fever or even GI bleeding, but none of these were present in the dogs in this study (Diez & 
Nguyen, 2010). Furthermore, the concentrations of urea and creatinine were within 
laboratory reference intervals in this study. 
Notwithstanding, after 12 weeks the urea concentrations decreased again in the treatment 
group, showing results similar to the control group and to week 1. The serum urea 
concentration is also dependent on the reabsorption in the kidneys, which is influenced by 
the filtrate flow in the renal tubules or GFR. Thus, an increased renal perfusion decreases 
its reabsorption, increasing its excretion in the urine, and the opposite, a reduction of renal 
perfusion results in an increase in renal tubule reabsorption of urea, increasing its 
concentration in the blood (Diez & Nguyen, 2010; Fettman  & Rebar, 2004). However, as 
mentioned previously high amounts of dietary protein increase the serum urea as well as 
clinical conditions that increase the catabolism of endogenous protein, while low-protein 
diets, anabolic drugs, hepatic insufficiency or portosystemic shunting can decrease urea. 
Nonetheless, obese individuals have a tendency to have increased GFR (Chagnac et al., 
2000; Wofford et al., 2001; Wuerzner et al., 2010). As mentions in the Yamka et al. study, 
obese dogs had lower values of urea than lean dogs (Yamka, et al., 2006). Consequently, 
the measurement of GFR during the study cloud help to differentiate from where was the 
decrease of urea. This measure was taken during the study but was not used for this study 
because the objective was to evaluate only the routine parameters. However, is necessary 
to take into account also the normal physiological variation of urea that can be the only 
reason in this study, because all the values was in the normal range (6-57 mg/dl, reference 
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from medvet) during the study. Furthermore, it is necessary to take into account that urea is 
not a reliable marker for GFR (Dibartola, 2010). 
The numerical decrease of serum creatinine concentration in the treatment group could be 
expected. As mentioned in the study of Yamka et al., obese dogs have lower values of 
creatinine than the lean dogs, which increase after a weight loss (Yamka, et al., 2006). 
Creatinine is inversely related to the GFR, which means an increase of GFR translates into 
a decrease in blood creatinine concentration (Lefebvre, Watson, Heiene, 2015), Thus, this 
result could be result of an increase in GFR, which is described in obese dogs (Henegar et 
al., 2001). Also in humans and experimental animal models increase of GFR is associated 
with obesity, which is due an increase of metabolic demands that result in glomerular 
hyperfiltation (Griffin et al., 2008). However, the control group had a similar trend with a 
decrease until week 12 and a slight increase following that point, showing no statistical 
significance between the two groups. Nonetheless the values of the two group were in the 
normal range (<1.4) mg/dl) and this result could be from normal physiologic variation that 
can occurs due to exercise, feeding, age, body size (Lefebvre, Watson, Heiene, 2015).  
The influence of body size on serum creatinine is related with quantity of muscle mass, 
which means an increase of muscle mass increases serum creatinine and vice versa 
(Lefebvre et al., 2015). Thus, other reason for the decrease of serum creatinine 
concentration could be due loss of muscle mass. Both groups were restricted to a limited 
space, which can contribute to less exercise and consequently slight reduction of muscle 
mass. A study performed by Bjornvad et al. of indoor-confined, adult neutered cats showed 
that the BCS underestimate the levels of body fat and although they seem skinny they have 
high level of body fat due to a lack of exercise (Bjornvad et al., 2011). As observed in 
humans, physical inactivity may result in a decrease in lean body mass, causing a relatively 
higher percentage of body fat, despite what appears to be a healthy bodyweight (Heber et 
al., 1996). However, all the values obtained are in the normal ranges and that from this 
study it is not possible to determine whether these absolute decreases or increases are of 
clinical significance. 
 
The results observed of USG (1.015 to 1.045) and UPCR (normal: <0.2 or borderline: 0.2 to 
0.5) were within laboratory reference intervals during the 24 weeks except for two dogs 
(one from the control group and another one from the treatment group).  
An increase on UPCR would be expected in the treatment group because obesity in 
humans can lead to proteinuria or albuminuria, and ORG (Chang et al., 2013; Praga et al., 
2000). In humans, the magnitude of proteinuria also correlates with the severity of obesity 
(Kambham et al., 2001). Also in dog a study performed by Tefft et al., UPCR is numerically 
higher in obese dog mainly in BCS of 8 or 9. However none of them developed proteinuria, 
and compared with the lean dogs these results did not show a statistical significant 
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difference (Tefft et al., 2014). A study of weight loss in obese dogs showed a decrease of 
UPCR after a weight loss (Tvarijonaviciute et al., 2013). From Table 8 it is possible to 
observe that UPCR increased lightly in the two groups. The increase in the two groups 
could be due to a higher GFR that can occur with the increase of protein in the diet or due 
to the glomerular lesions already mentioned. The latter could be also the reason for two 
dogs, one in the control group (UPCR 0.6 at week 24) and one in the treatment group 
(UPCR 0.65 at week 24) that had higher levels (which can also be seen by the higher level 
of standart desviation 0.19 and 0.18 for control group and for the treatment group 
respectively on week 24). One of them was one of the oldest (9 year old) in the experiment 
which may mean that this dog could have some renal damage due to the effect of the age 
that was not detected in the initial examination and makes them more sensitive to the 
excess of protein in the diet (Dibartola, 2010). The other dog the had a persistent 
proteinuria with results of UPCR: 0.25 at week 1 which means that is in borderline (0.2-0.5); 
0.98 at week 12 and 0.65 at week 24. In IRIS a patient is considered proteinuric by UPCR 
when has a values higher than 0.5, however the persistence of proteirunia have to be 
demonstrated by re-evaluating 2 to 4 weeks, that in this case was 12 week (Gregory, 2016). 
Proteinuria is associated with progression of CKD and the greater the magnitude of 
proteinuria, the greater the risk of renal disease progression and mortality (Jacob et al., 
2005). In humans, proteinuria is appears in ORG patients before the onset of azotemia 
(Kambham et al., 2001). Also in obese dog structural changes on the glomerulus may be 
precursors of more severe glomerular injury associated with prolonged obesity (Henegar et 
al., 2001). The realization of biopsies in this study could help to demonstrate if the 
proteinuria found in this dog was result of ORG.   
The results of USG did not show a significant difference through the time and the slight 
difference between the weeks can be just due physiologic variations. In dogs, urine 
osmolality varies widely during the day, which mean each dog, have a individual variation of 
USG that can be influenced by the effect of feeding or drinking behavior (Vonderen, 
Kooistra, Rijnberk, 1997). The hydration status of the animal is another factor that can 
change the USG, with deprivation of water the USG increase and a concentrate urine is 
present, while the opposite such as in polydipsia, a decrease of USG occurs (dilute urine) 
(Watson, Lefebvre, Elliott, 2015).  
However in this study would expect an increase a decrease on USG in the treatment group 
as a result of the increase of weight and consequently renal dysfunction. In the weight loss 
program of Tvarijonaviciute, weight loss resulted in an increase of USG, that could be 
representative of improved renal funtion through an increase in tubular concentrating ability 
(increased USG) and a decrease in protein filtered by the glomerulus (decreased UPCR) 




To monitor renal disease, veterinary clinicians rely primarily on serum creatinine and urea 
concentrations, USG, and UPCR, which quick to measure and easy to performed because 
only one sample of blood or urine is necessary (Murgier, Jakins, Bexfield, Archer, 2009). 
However, all of these tests are insensitive in detecting renal damage and dysfunction at an 
early stage (will be discussed further), since azotemia and impaired urine concentrating 
ability are only seen when at least 75% of the nephrons are damaged (Watson, 1998; 
Dibartola, 2010; Von Hendy-Willson & Pressler, 2011).  Other diagnostic modalities such as 
the evaluation of the GFR that is the gold standard could have helped further explain the 
results in this study. However, is not practical for the routine use. Thus, it is necessary to 
find practical renal markers to measure renal function. Symmetric dimethylarginine (SDMA), 
a new renal maker being developed as indirect measures of GFR, has shown to have 
higher sensitivity than current renal markers used in the clinical practice, and with the 
possibility of detecting patients with mildly reduced renal function (Hall et al., 2014). Until 
now, the available data suggest that plasma (or serum) concentration of symmetric SDMA 
reflects GFR in dogs (Nabity et al., 2013) and may be more sensitive than blood creatinine 
for detecting early stages of CKD (Hall et al., 2016), and also less affected by loss of lean 
body mass (Hall et al., 2015). 
Other main possibility for lack of significant changes in routine renal marker values as a 
result of weight gain are due to the fact that the dogs were not obese long enough to allow 
the detection of obese-related glomerulopathy, meaning that the study period might have 
been insufficient. Nevertheless, in one study of dogs with induced obesity, significant 
histologic, biochemical, and functional renal changes were noted with only a 7- to 9-week 
duration of obesity. In that study, however, the dogs experienced in just 9 weeks a 50% 
weight gain over their initial weight (Henegar et al., 2001) as already mention previously.  
Another possible cause for the results is that the number of animal groups was low, and in 
addition to that fact one of the dogs of the treatment group did not gain much weight, as 
already mentioned.  
 
In conclusion, the overweight dogs did not show the presence of glomerular disease, which 
can be evidenced by proteinuria, increase of creatinine or decrease of specific gravity, 
evaluated by routine markers of renal function in otherwise healthy overweight and obese 
dogs. Evaluation of a larger number and more markedly obese dogs may determine if ORG 
develops in obese dogs, or perhaps other renal markers should be used. Routine markers 
used in this study were not able to detect any changes in renal function at the beginning of 
obesity development. Therefore, it necessary to discover more specific and sensitive tests 
to evaluate renal function in the context of obesity-related kidney disease, given that there 
is a high risk of progression towards irreversible renal damage. Future studies will need to 
address the need of developing markers that enable early detection of renal dysfunction, as 
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well as to identify causal factors that might predispose to such dysfunction. New serum 
biomarkers for early renal injury have started to gain attention in veterinary medicine, 
namely the SDMA, which is beginning to become widespread throughout the veterinary 
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